

Thyroid cancer

NICE guideline: methods

NICE guideline NGXX

Methods

June 2022

Draft for Consultation

Developed by National Guideline Centre

Disclaimer

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.

Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the [Welsh Government](#), [Scottish Government](#), and [Northern Ireland Executive](#). All NICE guidance is subject to regular review and may be updated or withdrawn.

Copyright

© NICE, 2022. All rights reserved. Subject to Notice of rights.

ISBN:

Contents

1	Development of the guideline	5
1.1	Remit	5
2	Methods	6
2.1	Developing the review questions and outcomes	6
2.1.1	Stratification	10
2.2	Searching for evidence	10
2.2.1	Clinical and health economics literature searches	10
2.3	Reviewing evidence	11
2.3.1	Types of studies and inclusion and exclusion criteria	12
2.4	Methods of combining evidence	13
2.4.1	Data synthesis for intervention reviews	13
2.4.2	Data synthesis for diagnostic reviews	14
2.4.3	Data synthesis for qualitative reviews	15
2.5	Appraising the quality of evidence by outcomes	15
2.5.1	Intervention reviews	15
2.5.2	Diagnostic reviews	22
2.5.3	Qualitative reviews	24
2.6	Assessing clinical importance	26
2.7	Identifying and analysing evidence of cost effectiveness	27
2.7.1	Literature review	27
2.7.2	Undertaking new health economic analysis	29
2.7.3	Cost-effectiveness criteria	30
2.7.4	In the absence of health economic evidence	30
2.8	Developing recommendations	30
2.8.1	Research recommendations	32
2.8.2	Validation process	32
2.8.3	Updating the guideline	32
2.8.4	Disclaimer	32
2.8.5	Funding	33
2.9	Guideline-specific terms	33
2.10	General terms	37
	Acronyms and abbreviations	50
	References	52

1 Development of the guideline

2 1.1 Remit

3 NICE received the remit for this guideline from NHS England. NICE commissioned
4 the National Guideline Centre to produce the guideline.

5 The remit for this guideline is: thyroid cancer: assessment and management.

6 To see “What this guideline covers” and “What this guideline does not cover” please
7 see the guideline scope Thyroid cancer

2 Methods

This guideline was developed using the methods described in the NICE guidelines manual³ as outlined in Table 1 below.

Table 1 Versions of the NICE guidelines manual followed during guideline development and guideline validation

Stage	2018 update	2020 update
Scoping	✓	
Development	✓	
Validation		✓

Declarations of interest were recorded according to the NICE conflicts of interest policy.

2.1 Developing the review questions and outcomes

The review questions developed for this guideline were based on the key areas and draft review questions identified in the guideline scope. They were drafted by the National Guideline Centre technical team and refined and validated by the committee and signed off by NICE. A total of 19 review questions were developed in this guideline and outlined in Table 2.

The review questions were based on the following frameworks:

- population, intervention, comparator and outcome (PICO) for reviews of interventions (including test and treat)
- population, index tests, reference standard and target condition for reviews of diagnostic test accuracy
- population, setting and context for qualitative reviews.

This use of a framework informed a more detailed protocol that guided the literature searching process, critical appraisal and synthesis of evidence, and facilitated the development of recommendations by the guideline committee. Full literature searches, critical appraisals and evidence reviews were completed for all the specified review questions.

Table 2: Review questions

Evidence report	Type of review	Review questions	Outcomes
A Ultrasound	Diagnostic accuracy	What is the diagnostic accuracy of ultrasound for identifying thyroid nodule malignancies or nodules with malignant potential?	<ul style="list-style-type: none"> • Sensitivity • Specificity
A Ultrasound accuracy	Observational	In people with thyroid nodules on ultrasound at initial presentation, for what size and classification is it clinically and cost effective to use active surveillance or discharge rather than biopsy?	<ul style="list-style-type: none"> • Mortality • Quality of life • Local cancer progression • Incidence of distant Metastases • Decision to treat • Adverse events

Evidence report	Type of review	Review questions	Outcomes
B Blood tests	Diagnostic RCT	What is the clinical and cost effectiveness of 1) thyroid antibody blood tests, and 2) measurement of serum calcitonin, at initial presentation?	<ul style="list-style-type: none"> • Mortality • Quality of life (any validated scores) • Local cancer progression • Incidence of distant metastases • Cancer recurrence
C Radioisotope scan	Diagnostic RCT	What is the clinical and cost effectiveness of radioisotope scans for people with suspected thyroid cancer?	<ul style="list-style-type: none"> • Quality of life (any validated scores) • Local cancer progression • Incidence of distant metastases • Cancer recurrence • Delayed management • Unnecessary further investigations • Radiation-related adverse events (combined) • Change in patient management
D FNAC or biopsy	Diagnostic accuracy	For people with thyroid nodules that require further investigation following ultrasound, what is the diagnostic accuracy of FNAC with rapid on-site assessment, FNAC without rapid on-site assessment or core biopsy for diagnosing thyroid cancer?	<ul style="list-style-type: none"> • Sensitivity • Specificity
E Repeat FNAC	Diagnostic RCT	For people with fine-needle aspiration samples showing benign cytology or non-diagnostic features but with US / clinical findings indicative of increased risk of malignancy, is it clinically and cost effective to use diagnostic hemithyroidectomy, repeat FNAC, use active surveillance or discharge?	<ul style="list-style-type: none"> • Quality of life (any validated scores) • Thyroid cancer diagnosis
F Molecular testing	Diagnostic RCT	For people who have had fine-needle aspiration samples, where the FNAC sample was adequate but was not able to differentiate between benign and malignant samples, what is the clinical and cost effectiveness of molecular testing to diagnose or rule out thyroid cancer?	<ul style="list-style-type: none"> • Mortality • Quality of life • Disease progression
G Imaging	Diagnostic RCT	What are the indications for using CT (with or without contrast), MRI, PET or bone scans for further staging?	<ul style="list-style-type: none"> • Mortality • Quality of life • Progression of disease (not including imaging findings) • Adverse effects

Evidence report	Type of review	Review questions	Outcomes
H Initial treatment	Interventional	For people with differentiated thyroid cancer, what is the clinical and cost effectiveness of active surveillance, hemi-thyroidectomy (with or without prophylactic or therapeutic node dissection) or total thyroidectomy (with or without prophylactic or therapeutic node dissection)?	<ul style="list-style-type: none"> • Mortality • Quality of life • Cost effectiveness • Local cancer progression • Incidence of distant metastases • Cancer recurrence • Postoperative dysphagia • Recurrent nerve palsy • Hypoparathyroidism • Need for further treatment
I RAI with or without TSH	Interventional	What is the clinical and cost effectiveness of radioactive iodine with thyrotropin alfa versus radioactive iodine with withdrawal of thyroid hormone replacement?	<ul style="list-style-type: none"> • Mortality • Quality of life (any validated scales) • Local cancer progression (increase in size/number of tumours) • Incidence of distant metastases • Cancer recurrence • Successful ablation • Second primary malignancy
J RAI compared to no RAI	Interventional	What is the clinical and cost effectiveness of radioactive iodine (RAI) ablation/treatment versus no RAI ablation/treatment in different population groups, characterised by stage, type of differentiated cancer, existence of vascular infiltration and gender?	<ul style="list-style-type: none"> • Mortality • Quality of life (any validated tools) • Local cancer progression • Incidence of distant metastases • Cancer recurrence • Salivary gland disorders • Second primary malignancy
K RAI activity	Interventional	What is the most clinically and cost-effective administered activity for people receiving radioactive iodine after thyroidectomy?	<ul style="list-style-type: none"> • Successful ablation (thyroglobulin levels / USS / diagnostic RAI) • Mortality • Quality of life • Local cancer progression • Incidence of distant metastases • Cancer recurrence • Second primary malignancy
L External beam	Interventional	For people with residual, metastatic or recurrent thyroid cancer, what is the clinical and cost effectiveness of external beam radiotherapy?	<ul style="list-style-type: none"> • Mortality • Progression free survival • Quality of life (any validated scores)

Evidence report	Type of review	Review questions	Outcomes
radiotherapy			<ul style="list-style-type: none"> Local/regional cancer recurrence Cancer recurrence Postoperative dysphagia
M TSH suppression	Interventional	What is the clinical and cost effectiveness of TSH suppression versus no TSH suppression in different population groups, characterised by recurrence risk, ethnicity, gender and age?	<ul style="list-style-type: none"> Mortality Quality of life (any validated tools) Thyroglobulin levels Local cancer progression Incidence of distant metastases Cancer recurrence Osteoporosis Cardiac complications (reported or composite outcomes allowed) Second primary malignancy
N Duration of TSH suppression	Interventional	For people who have had thyroidectomy and radioactive iodine treatment for differentiated thyroid cancer, what is the most clinically and cost-effective length of treatment with drugs (such as levothyroxine) to suppress TSH to subnormal levels?	<ul style="list-style-type: none"> Thyroglobulin levels Mortality Quality of life (any validated scores) Local cancer progression Incidence of distant metastases Cancer recurrence Cardiovascular adverse effects Osteoporosis Second primary malignancy
O Measuring thyroglobulin	Interventional	For people who have had thyroidectomy and radioactive iodine for differentiated thyroid cancer, what is the clinical and cost effectiveness of measuring thyroglobulin and thyroglobulin antibodies (with or without radioisotope scans) to assess residual or recurrent disease?	<ul style="list-style-type: none"> Mortality Quality of life Local cancer progression Incidence of distant metastases Detection of residual disease or detection of recurrent disease when no residual disease seen
P Stimulated thyroglobulin	Interventional	For people who have had treatment for differentiated thyroid cancer, what is the clinical and cost effectiveness of using stimulated thyroglobulin or highly sensitive thyroglobulin assays, to re-assess risk of recurrence after initial treatment and to tailor their follow-up regimen?	<ul style="list-style-type: none"> Mortality Quality of life local cancer progression Incidence of distant metastases Cancer recurrence
Q	Interventional	1. For people who have had treatment for differentiated thyroid	<ul style="list-style-type: none"> Mortality

Evidence report	Type of review	Review questions	Outcomes
Length and frequency of follow-up		<p>cancer, what is the optimum frequency of follow-up according to the severity, spread of the disease and treatment given?</p> <p>2. For people who have had treatment for differentiated thyroid cancer, what is the optimum length of follow-up according to the severity, spread of the disease and treatment given?</p>	<ul style="list-style-type: none"> Quality of life Structural or biochemical* cancer progression of residual or known recurrent malignancy Structural or biochemical* cancer recurrence (distant/local)
R Information, education and support	Qualitative	What information, education and support do people with suspected and confirmed thyroid cancer and their families and carers need?	<ul style="list-style-type: none"> Thematic analysis will yield themes related to the types of information needed

1

2 2.1.1 Stratification

3 Stratification is applied where the committee are confident the intervention will work
4 differently in the groups and separate recommendations are required, therefore they
5 should be reviewed separately.

6 2.2 Searching for evidence

7 2.2.1 Clinical and health economics literature searches

8 The full strategy including population terms, intervention terms, study types applied,
9 the databases searched, and the years covered can be found in Appendix B of the
10 evidence review.

11 Systematic literature searches were undertaken to identify all published clinical and
12 health economic evidence relevant to the review questions. Searches were
13 undertaken according to the parameters stipulated within the NICE guideline's
14 manual, <https://www.nice.org.uk/process/pmg20/chapter/identifying-the-evidence-literature-searching-and-evidence-submission>.

16 Databases were searched using relevant medical subject headings, free-text terms
17 and study-type filters where appropriate. Studies published in languages other than
18 English were not reviewed, and where possible, searches were restricted to English
19 language. All searches were updated on between December 2021 and 13th January
20 2022. Papers published or added to databases after this date were not considered.
21 Where new evidence was identified, for example in consultation comments received
22 from stakeholders, the impact on the guideline was considered, and the action
23 agreed between NGC and NICE staff with a quality assurance role.

24 Searches were quality assured using different approaches prior to being run. Medline
25 search strategies were peer reviewed by a second information specialist using a QA
26 process based on the PRESS checklist². Key (seed) papers were checked if
27 retrieved.

1 Searching for unpublished literature was not undertaken.

2 Additional studies were added to the evidence base these consisted of references
3 included in relevant systematic reviews, and those highlighted by committee
4 members.

5 **2.3 Reviewing evidence**

6 The evidence for each review question was reviewed using the following process:

- 7 • Potentially relevant studies were identified from the search results by reviewing
8 titles and abstracts. The full papers were then obtained.
- 9 • Full papers were evaluated against the pre-specified inclusion and exclusion
10 criteria set out in the protocol to identify studies that addressed the review
11 question. The review protocols are included in an appendix to each of the
12 evidence reports.
- 13 • Relevant studies were critically appraised using the preferred study design
14 checklist as specified in the NICE guidelines manual⁴. The checklist used is
15 included in the individual review protocols in each of the evidence reports.
- 16 • Key information was extracted about interventional study methods and results into
17 'EviBase', NGC's purpose-built software. Summary evidence tables were
18 produced from data entered into EviBase, including critical appraisal ratings. Key
19 information about non-interventional study methods and results were manually
20 extracted into standard Word evidence tables (evidence tables are included in an
21 appendix to each of the evidence reports).

22 Summaries of the evidence were generated by outcome. Outcome data were
23 combined, analysed and reported according to study design:

- 24 ○ Randomised data were meta-analysed where appropriate and reported in
25 GRADE profile tables.
- 26 ○ Data from non-randomised studies were meta-analysed where appropriate and
27 reported in GRADE profile tables.
- 28 ○ Diagnostic data were meta-analysed where appropriate or presented as a
29 range of values in modified GRADE profile tables.
- 30 ○ Qualitative data were synthesised across studies using thematic analysis and
31 presented as summary statements in GRADE CERQual tables.
- 32 • A minimum of 10% of the abstracts were reviewed by two reviewers, with any
33 disagreements resolved by discussion or, if necessary, a third independent
34 reviewer.
- 35 • All of the evidence reviews were quality assured by a senior systematic reviewer.
36 This included checking:
 - 37 ○ papers were included or excluded appropriately
 - 38 ○ a sample of the data extractions
 - 39 ○ a sample of the risk of bias assessments
 - 40 ○ correct methods were used to synthesise data.

41 Discrepancies will be identified and resolved through discussion (with a third
42 reviewer where necessary).

1 2.3.1 Types of studies and inclusion and exclusion criteria

2 The inclusion and exclusion of studies was based on the criteria defined in the review
3 protocols, which can be found in an appendix to each of the evidence reports.
4 Excluded studies (with the reasons for their exclusion) are listed in an appendix to
5 each of the evidence reports. The committee was consulted about any uncertainty
6 regarding inclusion or exclusion.

7 Conference abstracts were not generally considered for inclusion. If abstracts were
8 included the authors were contacted for further information. Literature reviews,
9 posters, letters, editorials, comment articles, unpublished studies and studies not in
10 published in English language were excluded.

11 2.3.1.1 Type of studies

12 Randomised trials, non-randomised intervention studies, and other observational
13 studies (including diagnostic) were included in the evidence reviews as appropriate.

14 For intervention reviews, randomised controlled trials (RCTs) were included where
15 identified as because they are considered the most robust type of study design that
16 can produce an unbiased estimate of the intervention effects. Non-randomised
17 intervention studies were considered appropriate for inclusion if there was insufficient
18 randomised evidence for the committee to make a decision. In this case the
19 committee stated a priori in the protocol that either certain identified variables must
20 be equivalent at baseline or else the analysis had to adjust for any baseline
21 differences. If the study did not fulfil either criterion it was excluded. Refer to the
22 review protocols in each evidence report for full details on the study design of studies
23 that were appropriate for each review question.

24 For diagnostic review questions, diagnostic RCTs, cross-sectional studies and
25 retrospective studies were included. Case–control studies were not included.

26 Systematic reviews and meta-analyses conducted to the same methodological
27 standards as the NICE reviews were included within the evidence reviews in
28 preference to primary studies, where they were available and applicable to the review
29 questions and updated or added to where appropriate to the guideline review
30 question. Individual patient data (IPD) meta-analyses were preferentially included if
31 meeting the protocol and methodological criteria.

32 2.3.1.1.1 Qualitative studies

33 In the qualitative reviews, studies using focus groups, or structured or semi-
34 structured interviews were considered for inclusion. Survey data or other types of
35 questionnaires were only included if they provided analysis from open-ended
36 questions, but not if they reported descriptive quantitative data only.

37 Saturation of qualitative studies

38 Data extraction in qualitative reviews is a thorough process. A common approach
39 applied in systematic reviews of qualitative data is to stop extracting data once
40 saturation has been reached. In an exploratory review, where themes are not
41 predefined in the protocol, thematic or data extraction may be applied. For the
42 purposes of this review, extraction of information from relevant studies was stopped
43 when data saturation was reached, i.e. no new information was emerging for a

1 specific theme. This includes; studies that don't report any new themes additional to
2 those already identified in the review as well as not contributing additional information
3 to the existing themes, as well as studies which report a new theme but data from
4 other themes in the study doesn't contribute to the existing review themes. In the
5 latter scenario only the new theme data is extracted. These studies are not
6 specifically excluded from the review as they nevertheless fit the criteria defined in
7 the review protocol. Any studies for which data were not extracted due to data
8 saturation having been reached, but that fit the inclusion criteria of the protocol, were
9 listed in the table for studies 'identified but not extracted due to saturation' in an
10 appendix to the qualitative evidence review.

11 **2.4 Methods of combining evidence**

12 **2.4.1 Data synthesis for intervention reviews**

13 Meta-analyses were conducted using Cochrane Review Manager (RevMan5)
14 ¹¹software.

15 **2.4.1.1 Analysis of different types of data**

16 ***Dichotomous outcomes***

17 Fixed-effects (Mantel–Haenszel) techniques were used to calculate risk ratios
18 (relative risk, RR) for the binary outcomes. The absolute risk difference was also
19 calculated using GRADEpro¹ software, using the median event rate in the control arm
20 of the pooled results.

21 For binary variables where there were zero events in either arm or a less than 1%
22 event rate, Peto odds ratios, rather than risk ratios, were calculated as they are more
23 appropriate for data with a low number of events. Where there are zero events in
24 both arms, the risk difference was calculated and reported instead.

25 **Continuous outcomes**

26 Continuous outcomes were analysed using an inverse variance method for pooling
27 weighted mean differences.

28 Where the studies within a single meta-analysis had different scales of measurement
29 for the same outcomes, standardised mean differences were used (providing all
30 studies reported either change from baseline or final values rather than a mixture of
31 both); each different measure in each study was 'normalised' to the standard
32 deviation value pooled between the intervention and comparator groups in that same
33 study.

34 The means and standard deviations of continuous outcomes are required for meta-
35 analysis. However, in cases where standard deviations were not reported, the
36 standard error was calculated if the p values or 95% confidence intervals (95% CI)
37 were reported, and meta-analysis was undertaken with the mean and standard error
38 using the generic inverse variance method in Cochrane Review Manager
39 (RevMan5)¹¹ software.

1 **Generic inverse variance**

2 If a study reported only the summary statistic and 95% CI the generic-inverse
3 variance method was used to enter data into RevMan5¹¹. If the control event rate was
4 reported this was used to generate the absolute risk difference in GRADEpro.¹ If
5 multivariate analysis was used to derive the summary statistic but no adjusted control
6 event rate was reported no absolute risk difference was calculated.

7 **Complex analysis**

8 Where studies had used a crossover design, paired continuous data were extracted
9 where possible, and forest plots were generated in RevMan5 with the generic inverse
10 variance function. When a crossover study had categorical data and the number of
11 subjects with an event in both interventions was known, the standard error (of the log
12 of the risk ratio) was calculated using the simplified Mantel–Haenszel method for
13 paired outcomes. Forest plots were also generated in RevMan5¹¹ with the generic
14 inverse variance function. If paired continuous or categorical data were not available
15 from the crossover studies, the separate group data were analysed in the same way
16 as data from parallel groups, on the basis that this approach would overestimate the
17 confidence intervals and thus artificially reduce study weighting resulting in a
18 conservative effect. Where a meta-analysis included a mixture of studies using both
19 paired and parallel group approaches, all data were entered into RevMan5¹¹ using
20 the generic inverse variance function.

21 **2.4.2 Data synthesis for diagnostic reviews**

22 Two separate review protocols were produced to reflect the 2 different diagnostic
23 study designs.

24 **2.4.2.1 Diagnostic RCTs**

25 Diagnostic RCTs (sometimes referred to as test and treat trials) are a randomised
26 comparison of 2 diagnostic tests, with study outcomes being clinically important
27 consequences of the diagnosis (patient-related outcome measures similar to those in
28 intervention trials, such as mortality). Patients are randomised to receive test A or
29 test B, followed by identical therapeutic interventions based on the results of the test
30 (so someone with a positive result would receive the same treatment regardless of
31 whether they were diagnosed by test A or test B). Downstream patient outcomes are
32 then compared between the 2 groups. As treatment is the same in both arms of the
33 trial, any differences in patient outcomes will reflect the accuracy of the tests in
34 correctly establishing who does and does not have the condition. Data were
35 synthesised using the same methods for intervention reviews (see section 2.4.1.1
36 above).

37 **2.4.2.2 Diagnostic accuracy studies**

38 For diagnostic test accuracy studies, a positive result on the index test was found if
39 the person had values of the measured quantity above or below a threshold value,
40 and different thresholds could be used. The thresholds were pre-specified by the
41 committee including whether or not data could be pooled across a range of
42 thresholds. The threshold of a diagnostic test is defined as the value at which the test
43 can best differentiate between those with and without the target condition. In practice
44 this usually varies across studies. If a test has a high sensitivity then very few people
45 with the condition will be missed (few false negatives). For example, a test with a

1 sensitivity of 97% will only miss 3% of people with the condition. Conversely, if a test
2 has a high specificity then few people without the condition would be incorrectly
3 diagnosed (few false positives).

4 Coupled forest plots of the agreed primary paired outcome measure for decision
5 making (sensitivity and specificity) with their 95% CIs across studies (at various
6 thresholds) were produced for each test, using RevMan5¹¹. In order to do this, 2 by 2
7 tables (the number of true positives, false positives, true negatives and false
8 negatives) were directly taken from the study if given, or else were derived from raw
9 data or calculated from the set of test accuracy statistics.

10 Diagnostic meta-analysis was conducted where appropriate, that is, when 3 or more
11 studies were available per threshold. Test accuracy for the studies was pooled using
12 the bivariate method for the direct estimation of summary sensitivity and specificity
13 using a random-effects approach in WinBUGS software¹⁰¹². The advantage of this
14 approach is that it produces summary estimates of sensitivity and specificity that
15 account for the correlation between the 2 statistics. The bivariate method uses
16 logistic regression on the true positives, true negatives, false positives and false
17 negatives reported in the studies. Overall sensitivity and specificity and confidence
18 regions were plotted (using methods outlined by Novielli 2010.⁸) The pooled median
19 sensitivity and specificity and their 95% CIs were reported in the clinical evidence
20 summary tables. For analyses with fewer than 3 studies included, the results of the
21 study with the lower sensitivity value was reported when there were 2 studies, or
22 reported individually for a single study.

23 Heterogeneity or inconsistency amongst studies was visually inspected.

24 **2.4.3 Data synthesis for qualitative reviews**

25 The main findings for each included paper were identified and thematic analysis
26 methods were used to synthesise this information into broad overarching themes
27 which were summarised into the main review findings. The evidence was presented
28 in the form of a narrative summary detailing the evidence from the relevant papers
29 and how this informed the overall review finding plus a statement on the level of
30 confidence for that review finding. Considerable limitations and issues around
31 relevance were listed. A summary evidence table with the succinct summary
32 statements for each review finding was produced including the associated quality
33 assessment.

34 **2.5 Appraising the quality of evidence by outcomes**

35 **2.5.1 Intervention reviews**

36 The evidence for outcomes from the included RCTs and, where appropriate, non-
37 randomised intervention studies, were evaluated and presented using the 'Grading of
38 Recommendations Assessment, Development and Evaluation (GRADE) toolbox'
39 developed by the international GRADE working group
40 (<http://www.gradeworkinggroup.org/>). The software (GRADEpro¹) developed by the
41 GRADE working group was used to assess the quality of each outcome, taking into
42 account individual study quality and the meta-analysis results.

43 Each outcome was first examined for each of the quality elements listed and defined
44 in Table 3.

1 **Table 3: Description of quality elements in GRADE for intervention studies**

Quality element	Description
Risk of bias	Limitations in the study design and implementation may bias the estimates of the treatment effect. Major limitations in studies decrease the confidence in the estimate of the effect. Examples of such limitations are selection bias (often due to poor allocation concealment), performance and detection bias (often due to a lack of blinding of the patient, healthcare professional or assessor) and attrition bias (due to missing data causing systematic bias in the analysis).
Indirectness	Indirectness refers to differences in study population, intervention, comparator and outcomes between the available evidence and the review question.
Inconsistency	Inconsistency refers to an unexplained heterogeneity of effect estimates between studies in the same meta-analysis.
Imprecision	Results are imprecise when studies include relatively few patients and few events (or highly variable measures) and thus have wide confidence intervals around the estimate of the effect relative to clinically important thresholds. 95% confidence intervals denote the possible range of locations of the true population effect at a 95% probability, and so wide confidence intervals may denote a result that is consistent with conflicting interpretations (for example a result may be consistent with both clinical benefit AND clinical harm) and thus be imprecise.
Publication bias	Publication bias is a systematic underestimate or overestimate of the underlying beneficial or harmful effect due to the selective publication of studies. A closely related phenomenon is where some papers fail to report an outcome that is inconclusive, thus leading to an overestimate of the effectiveness of that outcome.
Other issues	Sometimes randomisation may not adequately lead to group equivalence of confounders, and if so this may lead to bias, which should be taken into account. Potential conflicts of interest, often caused by excessive pharmaceutical company involvement in the publication of a study, should also be noted.

2 Details of how the 4 main quality elements (risk of bias, indirectness, inconsistency
3 and imprecision) were appraised for each outcome are given below. Publication bias
4 was considered with the committee. If there was reason to suspect it was present, it
5 was explored with funnel plots. Funnel plots were constructed using RevMan5
6 software to assess against potential publication bias for outcomes containing more
7 than 5 studies. This was taken into consideration when assessing the quality of the
8 evidence.

9 2.5.1.1 Risk of bias

10 The main domains of bias for RCTs are listed in Table 4. Each outcome had its risk
11 of bias assessed within each study first using the appropriate checklist for the study
12 design (Cochrane RoB 2 for RCTs, or ROBINS-I for non-randomised studies or
13 ROBIS for systematic reviews). For each study, if there was no risk of bias in any
14 domain, the risk of bias was given a rating of 0; 'no serious risk of bias'. If there was
15 risk of bias in just 1 domain, the risk of bias was given a 'serious' rating of -1, but if
16 there was risk of bias in 2 or more domains the risk of bias was given a 'very serious'
17 rating of -2. An overall rating is calculated across all studies by taking into account
18 the weighting of studies according to study precision. For example if the most precise
19 studies tended to each have a score of -1 for that outcome, the overall score for that
20 outcome would tend towards -1.

1

Table 4: Principle domains of bias in randomised controlled trials

Limitation	Explanation
Selection bias (sequence generation and allocation concealment)	If those enrolling participants are aware of the group to which the next enrolled patient will be allocated, either because of a non-random sequence that is predictable, or because a truly random sequence was not concealed from the researcher, this may translate into systematic selection bias. This may occur if the researcher chooses not to recruit a participant into that specific group because of: <ul style="list-style-type: none"> • knowledge of that participant's likely prognostic characteristics, and • a desire for one group to do better than the other.
Performance and detection bias (lack of blinding)	Patients, caregivers, those adjudicating or recording outcomes, and data analysts should not be aware of the arm to which the participants are allocated. Knowledge of the group can influence: <ul style="list-style-type: none"> • the experience of the placebo effect • performance in outcome measures • the level of care and attention received, and • the methods of measurement or analysis all of which can contribute to systematic bias.
Attrition bias	Attrition bias results from an unaccounted for loss of data beyond a certain level (a differential of at least 10% between groups). Loss of data can occur when participants are compulsorily withdrawn from a group by the researchers (for example, when a per-protocol approach is used) or when participants do not attend assessment sessions. If the missing data are likely to be different from the data of those remaining in the groups, and there is a differential rate of such missing data from groups, systematic attrition bias may result.
Selective outcome reporting	Reporting of some outcomes and not others on the basis of the results can also lead to bias, as this may distort the overall impression of efficacy.
Other limitations	For example: <ul style="list-style-type: none"> • Stopping early for benefit observed in randomised trials, in particular in the absence of adequate stopping rules. • Use of unvalidated patient-reported outcome measures. • Lack of washout periods to avoid carry-over effects in crossover trials. • Recruitment bias in cluster-randomised trials.

2

The assessment of risk of bias differs for non-randomised intervention studies, as they are inherently at higher risk of bias due to the possibility of confounding and the greater risk of selection bias. The assessment of risk of bias therefore involves consideration of more domains and varies by study type. **Table 5** shows the domains considered for most types of non-randomised studies.

3

4

5

6

7

Table 5 Principle domains of bias in non-randomised studies

Bias	Explanation
Pre-intervention	
Confounding bias	Baseline confounding occurs when one or more prognostic variables (factors that predict the outcome of interest) also predicts the intervention received at baseline. ROBINS-I can also address time-varying confounding, which occurs when post-baseline prognostic factors affect the intervention received after baseline.
Selection bias	When exclusion of some eligible participants, or the initial follow-up time of some participants, or some outcome events, is related to both intervention and outcome, there will be an association between interventions and outcome even

Bias	Explanation
	if the effect of interest is truly null. This type of bias is distinct from confounding. A specific example is bias due to the inclusion of prevalent users, rather than new users, of an intervention.
At intervention	
Information bias	Bias introduced by either differential or non-differential misclassification of intervention status. Non-differential misclassification is unrelated to the outcome and will usually bias the estimated effect of intervention towards the null. Differential misclassification occurs when misclassification of intervention status is related to the outcome or the risk of the outcome.
Post-intervention	
Confounding bias	Bias that arises when there are systematic differences between experimental intervention and comparator groups in the care provided, which represent a deviation from the intended intervention(s). Assessment of bias in this domain will depend on the effect of interest (either the effect of assignment to intervention or the effect of adhering to intervention).
Selection bias	Bias that arises when later follow-up is missing for individuals initially included and followed (e.g. differential loss to follow-up that is affected by prognostic factors); bias due to exclusion of individuals with missing information about intervention status or other variables such as confounders.
Information bias	Bias introduced by either differential or non-differential errors in measurement of outcome data. Such bias can arise when outcome assessors are aware of intervention status, if different methods are used to assess outcomes in different intervention groups, or if measurement errors are related to intervention status or effects.
Reporting bias	Selective reporting of results from among multiple measurements of the outcome, analyses or subgroups in a way that depends on the findings.

1 2.5.1.2 Indirectness

2 Indirectness refers to the extent to which the populations, interventions, comparisons
3 and outcome measures are dissimilar to those defined in the inclusion criteria for the
4 reviews. Indirectness is important when these differences are expected to contribute
5 to a difference in effect size, or may affect the balance of harms and benefits
6 considered for an intervention. As for the risk of bias, each outcome had its
7 indirectness assessed within each study first. For each study, if there were no
8 sources of indirectness, indirectness was given a rating of 0. If there was indirectness
9 in just 1 source (for example in terms of population), indirectness was given a
10 'serious' rating of -1, but if there was indirectness in 2 or more sources (for example,
11 in terms of population and treatment) the indirectness was given a 'very serious'
12 rating of -2. An overall rating is calculated across all studies by taking into account
13 the weighting of studies according to study precision. For example, if the most
14 precise studies tended to have an indirectness score of -1 each for that outcome, the
15 overall score for that outcome would tend towards -1.

16 2.5.1.3 Inconsistency

17
18 Inconsistency refers to an unexplained heterogeneity of results for an outcome
19 across different studies. When estimates of the treatment effect across studies differ
20 widely, this suggests true differences in the underlying treatment effect, which may
21 be due to differences in populations, settings or doses. Statistical heterogeneity was
22 assessed for each meta-analysis estimate by an I-squared (I^2) inconsistency statistic.

1 Heterogeneity or inconsistency amongst studies was also visually inspected. Where
2 statistical heterogeneity as defined above was present or there was clear visual
3 heterogeneity not captured in the I^2 value predefined subgrouping of studies was
4 carried out according to the protocol. See the review protocols for the subgrouping
5 strategy.

6 When heterogeneity existed within an outcome ($I^2 > 50\%$), but no plausible
7 explanation could be found, the quality of evidence for that outcome was
8 downgraded. Inconsistency for that outcome was given a 'serious' score of -1 if the I^2
9 was 50–74%, and a 'very serious' score of -2 if the I^2 was 75% or more.

10 If inconsistency could be explained based on pre-specified subgroup analysis (that is,
11 each subgroup had an $I^2 < 50\%$) then each of the derived subgroups were presented
12 separately for that forest plot (providing at least 2 studies remained in each
13 subgroup). The committee took this into account and considered whether to make
14 separate recommendations based on the variation in effect across subgroups within
15 the same outcome. In such a situation the quality of evidence was not downgraded.

16 If all predefined strategies of subgrouping were unable to explain statistical
17 heterogeneity, then a random effects (DerSimonian and Laird) model was employed
18 to the entire group of studies in the meta-analysis. A random-effects model assumes
19 a distribution of populations, rather than a single population. This leads to a widening
20 of the confidence interval around the overall estimate. If, however, the committee
21 considered the heterogeneity was so large that meta-analysis was inappropriate,
22 then the results were not pooled and were described narratively.

23 2.5.1.4 Imprecision

24 The criteria applied for imprecision were based on the 95% CIs for the pooled
25 estimate of effect, and the minimal important differences (MID) for the outcome. The
26 MIDs are the threshold for appreciable benefits and harms, separated by a zone
27 either side of the line of no effect where there is assumed to be no clinically important
28 effect. If either end of the 95% CI of the overall estimate of effect crossed 1 of the
29 MID lines, imprecision was regarded as serious and a 'serious' score of -1 was
30 given. This was because the overall result, as represented by the span of the
31 confidence interval, was consistent with 2 interpretations as defined by the MID (for
32 example, both no clinically important effect and clinical benefit were possible
33 interpretations). If both MID lines were crossed by either or both ends of the 95% CI
34 then imprecision was regarded as very serious and a 'very serious' score of -2 was
35 given. This was because the overall result was consistent with all 3 interpretations
36 defined by the MID (no clinically important effect, clinical benefit and clinical harm).
37 This is illustrated in Figure 1.

38 The value / position of the MID lines is ideally determined by values reported in the
39 literature. 'Anchor-based' methods aim to establish clinically meaningful changes in a
40 continuous outcome variable by relating or 'anchoring' them to patient-centred
41 measures of clinical effectiveness that could be regarded as gold standards with a
42 high level of face validity. For example, a MID for an outcome could be defined by the
43 minimum amount of change in that outcome necessary to make patients feel their
44 quality of life had 'significantly improved'. MIDs in the literature may also be based on
45 expert clinician or consensus opinion concerning the minimum amount of change in a
46 variable deemed to affect quality of life or health.

1 In the absence of values identified in the literature, the alternative approach to
2 deciding on MID levels is to use the modified GRADE 'default' values, as follows:


- 3 • For dichotomous outcomes the MIDs were taken to be RRs of 0.8* and 1.25. For
4 'positive' outcomes such as 'patient satisfaction', the RR of 0.8 is taken as the line
5 denoting the boundary between no clinically important effect and a clinically
6 important harm, whilst the RR of 1.25 is taken as the line denoting the boundary
7 between no clinically important effect and a clinically important benefit. For
8 'negative' outcomes such as 'bleeding', the opposite occurs, so the RR of 0.8 is
9 taken as the line denoting the boundary between no clinically important effect and
10 a clinically important benefit, whilst the RR of 1.25 is taken as the line denoting the
11 boundary between no clinically important effect and a clinically important harm.
12 There aren't established default values for ORs and the same values (0.8 and
13 1.25) are applied here but are acknowledged as arbitrary thresholds agreed by the
14 committee.
 - 15 ○ In cases where there are zero events in one arm of a single study, or some or
16 all of the studies in one arm of a meta-analysis, the same process is followed
17 as for dichotomous outcomes. However if there are no events in either arm in a
18 meta-analysis (or in a single unpooled study) the sample size is used to
19 determine imprecision using the following rule of thumb:
 - 20 – No imprecision: sample size ≥ 350
 - 21 – Serious imprecision: sample size ≥ 70 but < 350
 - 22 – Very serious imprecision: sample size < 70 .
 - 23 ○ When there was more than one study in an analysis and zero events occurred
24 in both groups for some but not all of the studies across both arms, the
25 optimum information size was used to determine imprecision using the
26 following guide:
 - 27 – No imprecision: $> 90\%$ power
 - 28 – Serious imprecision: $80-90\%$ power
 - 29 – Very serious imprecision: $< 80\%$ power.
- 30 • For continuous outcome variables the MID was taken as half the median baseline
31 standard deviation of that variable, across all studies in the meta-analysis. Hence
32 the MID denoting the minimum clinically important benefit was positive for a
33 'positive' outcome (for example, a quality of life measure where a higher score
34 denotes better health), and negative for a 'negative' outcome (for example, a
35 visual analogue scale [VAS] pain score). Clinically important harms will be the
36 converse of these. If baseline values are unavailable, then half the median
37 comparator group standard deviation of that variable will be taken as the MID. As
38 these vary for each outcome per review, details of the values used are reported in
39 the footnotes of the relevant GRADE summary table.
- 40 • If standardised mean differences have been used, then the MID was set at the
41 absolute value of +0.5. This follows because standardised mean differences are
42 mean differences normalised to the pooled standard deviation of the 2 groups,
43 and are thus effectively expressed in units of 'numbers of standard deviations'.
44 The 0.5 MID value in this context therefore indicates half a standard deviation, the
45 same definition of MID as used for non-standardised mean differences.

46 *NB GRADE report the default values as 0.75 and 1.25. These are consensus
47 values. This guideline follows NICE process to use modified values of 0.8 and 1.25
48 as they are symmetrical on a relative risk scale.

1 The default MID value was subject to amendment after discussion with the
 2 committee. If the committee decided that the MID level should be altered, after
 3 consideration of absolute as well as relative effects, this was allowed, provided that
 4 any such decision was not influenced by any bias towards making stronger or weaker
 5 recommendations for specific outcomes.

6 For this guideline, no appropriate MIDs for continuous or dichotomous outcomes
 7 were found in the literature, and so the default method was adopted.

8
 9
Figure 1: Illustration of precise and imprecise outcomes based on the 95% CI of dichotomous outcomes in a forest plot (Note that all 3 results would be pooled estimates, and would not, in practice, be placed on the same forest plot)



10 2.5.1.5 Overall grading of the quality of clinical evidence

11 Once an outcome had been appraised for the main quality elements, as above, an
 12 overall quality grade was calculated for that outcome. The scores (0, -1 or -2) from
 13 each of the main quality elements were summed to give a score that could be
 14 anything from 0 (the best possible) to -8 (the worst possible). However scores were
 15 capped at -3. This final score was then applied to the starting grade that had
 16 originally been applied to the outcome by default, based on study design. RCTs start
 17 at High, the overall quality became Moderate, Low or Very Low if the overall score
 18 was -1, -2 or -3 points respectively. The significance of these overall ratings is
 19 explained in Table 6. The reasons for downgrading in each case are specified in the
 20 footnotes of the GRADE tables.

1 **Table 6: Overall quality of outcome evidence in GRADE**

Level	Description
High	Further research is very unlikely to change our confidence in the estimate of effect
Moderate	Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate
Low	Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate
Very low	Any estimate of effect is very uncertain

2 **2.5.2 Diagnostic reviews**3 **2.5.2.1 Diagnostic RCTs**

4 Appraising the quality of evidence from diagnostic RCTs follows the same process as
5 section 2.5.1 for intervention reviews.

6 **2.5.2.2 Diagnostic test accuracy**7 **2.5.2.2.1 Risk of bias**

8 Risk of bias and indirectness of evidence for diagnostic data were evaluated by study
9 using the Quality Assessment of Diagnostic Accuracy Studies version 2 (QUADAS-2)
10 checklists (see appendix H in the NICE guidelines manual 2014⁴ Risk of bias and
11 applicability in primary diagnostic accuracy studies in QUADAS-2 consists of 4
12 domains (see **Table 7**):

- 13 • patient selection
- 14 • index test
- 15 • reference standard
- 16 • flow and timing.

17 **Table 7 Summary of QUADAS-2 with list of signalling, risk of bias and**
18 **applicability questions.**

Domain	Patient selection	Index test	Reference standard	Flow and timing
Description	Describe methods of patient selection. Describe included patients (prior testing, presentation, intended use of index test and setting)	Describe the index test and how it was conducted and interpreted	Describe the reference standard and how it was conducted and interpreted	Describe any patients who did not receive the index test(s) and/or reference standard or who were excluded from the 2×2 table (refer to flow diagram). Describe the time interval and any interventions between index test(s) and reference standard
Signalling questions (yes/no/unclear)	Was a consecutive or random sample of patients enrolled?	Were the index test results interpreted without	Is the reference standard likely to correctly classify	Was there an appropriate interval between index test(s)

Domain	Patient selection	Index test	Reference standard	Flow and timing
		knowledge of the results of the reference standard?	the target condition?	and reference standard?
	Was a case–control design avoided?	If a threshold was used, was it pre-specified?	Were the reference standard results interpreted without knowledge of the results of the index test?	Did all patients receive a reference standard?
	Did the study avoid inappropriate exclusions?			Did all patients receive the same reference standard?
				Were all patients included in the analysis?
Risk of bias; (high/low/unclear)	Could the selection of patients have introduced bias?	Could the conduct or interpretation of the index test have introduced bias?	Could the reference standard, its conduct or its interpretation have introduced bias?	Could the patient flow have introduced bias?
Concerns regarding applicability (high/low/unclear)	Are there concerns that the included patients do not match the review question?	Are there concerns that the index test, its conduct, or interpretation differ from the review question?	Are there concerns that the target condition as defined by the reference standard does not match the review question?	

12.5.2.2.2 *Inconsistency*

2 Inconsistency refers to an unexplained heterogeneity of results for an outcome
3 across different studies. Inconsistency was assessed by visual inspection of the
4 primary outcome measures (sensitivity and specificity) using the point estimates and
5 95% CIs of the individual studies on the forest plots or the summary value if a
6 diagnostic meta-analysis had been conducted. The evidence was downgraded by 1
7 increment if there was no overlap of 95% confidence intervals or by 2 increments if
8 there was wide variability. Where only a single study reports an outcome,
9 inconsistency is rated as ‘not detected’.

102.5.2.2.3 *Imprecision*

11 The judgement of precision was based on visual inspection of the confidence region
12 around the summary sensitivity and specificity point from the diagnostic meta-
13 analysis, if a diagnostic meta-analysis was conducted. Where a diagnostic meta-
14 analysis was not conducted, imprecision was assessed according to the range of
15 point estimates or, if only one study contributed to the evidence, the 95% CI around
16 the single study. The decision thresholds set by the committee were used to
17 determine whether imprecision is not serious, serious or very serious depending on
18 whether confidence intervals cross zero, one or two thresholds.

12.5.2.2.4 Overall grading

Quality rating started at high for prospective and retrospective cross-sectional studies, and each major limitation (risk of bias, indirectness, inconsistency and imprecision) brought the rating down by 1 increment to a minimum grade of very low, as explained for intervention reviews. This was presented in a modified GRADE profile.

2.5.3 Qualitative reviews

Review findings from the included qualitative studies were evaluated and presented using the 'Confidence in the Evidence from Reviews of Qualitative Research' (CERQual) Approach developed by the GRADE-CERQual Project Group, a subgroup of the GRADE Working Group.

The CERQual Approach assesses the extent to which a review finding is a reasonable representation of the phenomenon of interest (the focus of the review question). Each review finding was assessed for each of the 4 quality elements listed and defined below in Table 8.

Table 8: Description of quality elements in GRADE-CERQual for qualitative studies

Quality element	Description
Methodological limitations	The extent of problems in the design or conduct of the included studies that could decrease the confidence that the review finding is a reasonable representation of the phenomenon of interest. Assessed at the study level using the CASP checklist.
Coherence	The extent to how clear and cogent the fit is between the data from the primary studies and the review finding.
Relevance	The extent to which the body of evidence from the included studies is applicable to the context (study population, phenomenon of interest, setting) specified in the protocol.
Adequacy	The degree of the confidence that the review finding is being supported by sufficient data. This is an overall determination of the richness (depth of analysis) and quantity of the evidence supporting a review finding or theme.

Details of how the 4 quality elements (methodological limitations, coherence, relevance and adequacy) were appraised for each review finding are given below.

2.5.3.1 Methodological limitations

Each review finding had its methodological limitations assessed within each study first using the CASP checklist. Based on the degree of methodological limitations, studies were evaluated as having minor, moderate or severe limitations. A summary of the domains and questions covered is given below.

Table 9: Description of limitations assessed in the CASP checklist for qualitative studies

Domain	Aspects considered
Are the results valid?	<ul style="list-style-type: none"> Was there a clear statement of the aims of the research? Is qualitative methodology appropriate?

Domain	Aspects considered
	<ul style="list-style-type: none"> • Was the research design appropriate to address the aims of the research? • Was the recruitment strategy appropriate to the aims of the research? • Was the data collected in a way that addressed the research issue? • Has the relationship between researcher and participants been adequately considered?
What are the results?	Have ethical issues been taken into consideration? Was the data analysis sufficiently rigorous? Is there a clear statement of findings?
Will the results help locally?	How valuable is the research?

1 The overall assessment of the methodological limitations of the evidence was based
 2 on the limitations of the primary studies contributing to the review finding. The relative
 3 contribution of each study to the overall review finding and of the type of
 4 methodological limitation(s) were taken into account when giving an overall rating of
 5 concerns for this component.

6 **2.5.3.2 Relevance**

7 Relevance is the extent to which the body of evidence from the included studies is
 8 applicable to the context (study population, phenomenon of interest, setting)
 9 specified in the protocol. As such, relevance is dependent on the individual review
 10 and discussed with the guideline committee.

11 **2.5.3.3 Coherence**

12 Coherence is the extent to which the reviewer is able to identify a clear pattern
 13 across the studies included in the review, and if there is variation present (contrasting
 14 or disconfirming data) whether this variation is explained by the contributing study
 15 authors. For example, if a review finding in 1 study does not support the main finding
 16 and there is no plausible explanation for this variation, or if there is ambiguity in the
 17 descriptions in the primary data, then the confidence that the main finding reasonably
 18 reflects the phenomenon of interest is decreased.

19 **2.5.3.4 Adequacy**

20 The judgement of adequacy is based on the confidence of the finding being
 21 supported by sufficient data. This is an overall determination of the richness (and
 22 quantity of the evidence supporting a review finding or theme. Rich data provide
 23 sufficient detail to gain an understanding of the theme or review finding, whereas thin
 24 data do not provide enough detail for an adequate understanding. Quantity of data is
 25 the second pillar of the assessment of adequacy. For review findings that are only
 26 supported by 1 study or data from only a small number of participants, the confidence
 27 that the review finding reasonably represents the phenomenon of interest might be
 28 decreased because there is less confidence that studies undertaken in other settings
 29 or participants would have reported similar findings. As with richness of data, quantity
 30 of data is review dependent. Based on the overall judgement of adequacy, a rating of
 31 no concerns, minor concerns, or substantial concerns about adequacy was given.

1 2.5.3.5 Overall judgement of the level of confidence for a review finding

2 GRADE-CERQual is used to assess the body of evidence as a whole through a
3 confidence rating representing the extent to which a review finding is a reasonable
4 representation of the phenomenon of interest. For each of the above components,
5 level of concern is categorised as either;

- 6 • no or very minor concerns
- 7 • minor concerns
- 8 • moderate concerns, or
- 9 • serious concerns.

10 The concerns from the 4 components (methodological limitations, coherence,
11 relevance and adequacy) are used in combination to form an overall judgement of
12 confidence in the finding. GRADE-CERQual uses 4 levels of confidence: high,
13 moderate, low and very low confidence. The significance of these overall ratings is
14 explained in Table 10. Each review finding starts at a high level of confidence and is
15 downgraded based on the concerns identified in any 1 or more of the 4 components.
16 Quality assessment of qualitative reviews is a subjective judgement by the reviewer
17 based on the concerns that have been noted. An explanation of how such a
18 judgement had been made for each component is included in the footnotes of the
19 summary of evidence tables.

20 **Table 10: Overall level of confidence for a review finding in GRADE-CERQual**

Level	Description
High confidence	It is highly likely that the review finding is a reasonable representation of the phenomenon of interest.
Moderate confidence	It is likely that the review finding is a reasonable representation of the phenomenon of interest.
Low confidence	It is possible that the review finding is a reasonable representation of the phenomenon of interest.
Very low confidence	It is not clear whether the review finding is a reasonable representation of the phenomenon of interest.

21 2.6 Assessing clinical importance

22 The committee assessed the evidence by outcome in order to determine if there was,
23 or potentially was, a clinically important benefit, a clinically important harm or no
24 clinically important difference between interventions. To facilitate this, binary
25 outcomes were converted into absolute risk differences (ARDs) using GRADEpro¹
26 software: the median control group risk across studies was used to calculate the
27 ARD and its 95% CI from the pooled risk ratio.

28 The assessment of clinical benefit, harm, or no benefit or harm was based on the
29 point estimate of absolute effect for intervention studies, which was standardised
30 across the reviews.

31 For continuous outcomes if the mean difference was greater than the minimally
32 important difference (MID) then this represented a clinical benefit or harm. For
33 outcomes such as mortality any reduction or increase was considered to be clinically
34 important.

35 For continuous outcomes where the GRADE default MID has been used, the values
36 for each outcome are provided in the footnotes of the relevant GRADE tables.

2.7 Identifying and analysing evidence of cost effectiveness

The committee is required to make decisions based on the best available evidence of both clinical effectiveness and cost effectiveness. Guideline recommendations should be based on the expected costs of the different options in relation to their expected health benefits (that is, their 'cost effectiveness') rather than the total implementation cost. However, the committee will also need to be increasingly confident in the cost effectiveness of a recommendation as the cost of implementation increases. Therefore, the committee may require more robust evidence on the effectiveness and cost effectiveness of any recommendations that are expected to have a substantial impact on resources; any uncertainties must be offset by a compelling argument in favour of the recommendation. The cost impact or savings potential of a recommendation should not be the sole reason for the committee's decision⁴.

Health economic evidence was sought relating to the key clinical issues being addressed in the guideline. Health economists:

- Undertook a systematic review of the published economic literature.
- Undertook new cost-effectiveness analysis in priority areas.

2.7.1 Literature review

The health economists:

- Identified potentially relevant studies for each review question from the health economic search results by reviewing titles and abstracts. Full papers were then obtained.
- Reviewed full papers against prespecified inclusion and exclusion criteria to identify relevant studies (see below for details).
- Critically appraised relevant studies using economic evaluations checklists as specified in the NICE guidelines manual⁴.
- Extracted key information about the studies' methods and results into health economic evidence tables (which can be found in appendices to the relevant evidence reports).
- Generated summaries of the evidence in NICE health economic evidence profile tables (included in the relevant evidence report for each review question) – see below for details.

2.7.1.1 Inclusion and exclusion criteria

Full economic evaluations (studies comparing costs and health consequences of alternative courses of action: cost–utility, cost-effectiveness, cost–benefit and cost–consequences analyses) and comparative costing studies that addressed the review question in the relevant population were considered potentially includable as health economic evidence.

Studies that only reported cost per hospital (not per patient), or only reported average cost effectiveness without disaggregated costs and effects were excluded. Literature reviews, abstracts, posters, letters, editorials, comment articles, unpublished studies and studies not in English were excluded. Studies published before 2005 and studies from non-OECD countries or the USA were also excluded, on the basis that the

1 applicability of such studies to the present UK NHS context is likely to be too low for
2 them to be helpful for decision-making.

3 Remaining health economic studies were prioritised for inclusion based on their
4 relative applicability to the development of this guideline and the study limitations. For
5 example, if a high quality, directly applicable UK analysis was available, then other
6 less relevant studies may not have been included. Where exclusions occurred on this
7 basis, this is noted in the relevant evidence report.

8 For more details about the assessment of applicability and methodological quality
9 see **Table 11** below and the economic evaluation checklist (appendix H of the NICE
10 guidelines manual⁴) and the health economics review protocol, which can be found in
11 each of the evidence reports.

12 When no relevant health economic studies were found from the economic literature
13 review, relevant UK NHS unit costs related to the compared interventions were
14 presented to the committee to inform the possible economic implications of the
15 recommendations.

16 2.7.1.2 NICE health economic evidence profiles

17 NICE health economic evidence profile tables were used to summarise cost and
18 cost-effectiveness estimates for the included health economic studies in each
19 evidence review report. The health economic evidence profile shows an assessment
20 of applicability and methodological quality for each economic study, with footnotes
21 indicating the reasons for the assessment. These assessments were made by the
22 health economist using the economic evaluation checklist from the NICE guidelines
23 manual⁴. It also shows the incremental costs, incremental effects (for example,
24 quality-adjusted life years [QALYs]) and incremental cost-effectiveness ratio (ICER)
25 for the base case analysis in the study, as well as information about the assessment
26 of uncertainty in the analysis. See **Table 11** for more details.

27 When a non-UK study was included in the profile, the results were converted into
28 pounds sterling using the appropriate purchasing power parity⁹.

29 **Table 11: Content of NICE health economic evidence profile**

Item	Description
Study	Surname of first author, date of study publication and country perspective with a reference to full information on the study.
Applicability	An assessment of applicability of the study to this guideline, the current NHS situation and NICE decision-making: ^(a) <ul style="list-style-type: none"> • Directly applicable – the study meets all applicability criteria, or fails to meet 1 or more applicability criteria but this is unlikely to change the conclusions about cost effectiveness. • Partially applicable – the study fails to meet 1 or more applicability criteria, and this could change the conclusions about cost effectiveness. • Not applicable – the study fails to meet 1 or more of the applicability criteria, and this is likely to change the conclusions about cost effectiveness. Such studies would usually be excluded from the review.
Limitations	An assessment of methodological quality of the study: ^(a) <ul style="list-style-type: none"> • Minor limitations – the study meets all quality criteria, or fails to meet 1 or more quality criteria, but this is unlikely to change the conclusions about cost effectiveness.

Item	Description
	<ul style="list-style-type: none"> • Potentially serious limitations – the study fails to meet 1 or more quality criteria, and this could change the conclusions about cost effectiveness. • Very serious limitations – the study fails to meet 1 or more quality criteria, and this is highly likely to change the conclusions about cost effectiveness. Such studies would usually be excluded from the review.
Other comments	Information about the design of the study and particular issues that should be considered when interpreting it.
Incremental cost	The mean cost associated with one strategy minus the mean cost of a comparator strategy.
Incremental effects	The mean QALYs (or other selected measure of health outcome) associated with one strategy minus the mean QALYs of a comparator strategy.
Cost effectiveness	Incremental cost-effectiveness ratio (ICER): the incremental cost divided by the incremental effects (usually in £ per QALY gained).
Uncertainty	A summary of the extent of uncertainty about the ICER reflecting the results of deterministic or probabilistic sensitivity analyses, or stochastic analyses of trial data, as appropriate.

(a) *Applicability and limitations were assessed using the economic evaluation checklist in appendix H of the NICE guidelines manual⁴*

1
2

3 2.7.2 Undertaking new health economic analysis

4 As well as reviewing the published health economic literature for each review
5 question, as described above, new health economic analysis was undertaken by the
6 health economist in selected areas. Priority areas for new analysis were agreed by
7 the committee after formation of the review questions and consideration of the
8 existing health economic evidence.

9 The committee identified the management of people with indeterminate or non-
10 diagnostic cytology after a fine-needle aspiration (FNA) as the higher priority areas
11 for original health economic model. The committee decided that identifying the most
12 cost-effective diagnostic pathway for people with an inconclusive FNAC was
13 important given the large number of FNACs performed each year and the high rate of
14 inconclusive results (around 35%-40%). The second area identified as high priority
15 was whether recombinant human thyroid stimulating hormone (rhTSH) was cost-
16 effective compared to thyroid hormone withdrawal (THW) in people preparing to
17 receive radioactive iodine ablation (RAI). This question had a potentially large impact
18 due to the high cost of Thyrotropin Alpha, the rhTSH drug used in England. Initially,
19 this area had lower priority due to the availability of several published economic
20 evaluations; however, priority was later increased when it became clear that there
21 was a large heterogeneity among the clinical trials informing the economic
22 evaluations. Consequently, an original economic evaluation using a meta-analysis of
23 all available trials was conducted.

24 The following general principles were adhered to in developing the cost-effectiveness
25 analyses:

- 26 • Methods were consistent with the NICE reference case for interventions with
27 health outcomes in NHS settings³⁴.
- 28 • The committee was involved in the design of the model, selection of inputs and
29 interpretation of the results.
- 30 • Model inputs were based on the systematic review of the clinical literature
31 supplemented with other published data sources where possible.

- 1 • When published data were not available committee expert opinion was used to
- 2 populate the model.
- 3 • Model inputs and assumptions were reported fully and transparently.
- 4 • The results were subject to sensitivity analysis and limitations were discussed.
- 5 • The model was peer-reviewed: both models were peer-reviewed by two senior
- 6 health economists at the NGC.

7 **2.7.3 Cost-effectiveness criteria**

8 NICE sets out the principles that committees should consider when judging whether
9 an intervention offers good value for money^{6, 74}. In general, an intervention was
10 considered to be cost effective (given that the estimate was considered plausible) if
11 either of the following criteria applied:

- 12 • the intervention dominated other relevant strategies (that is, it was both less costly
13 in terms of resource use and more clinically effective compared with all the other
14 relevant alternative strategies), or
- 15 • the intervention cost less than £20,000 per QALY gained compared with the next
16 best strategy.

17 If the committee recommended an intervention that was estimated to cost more than
18 £20,000 per QALY gained, or did not recommend one that was estimated to cost less
19 than £20,000 per QALY gained, the reasons for this decision are discussed explicitly
20 in 'The committee's discussion of the evidence' section of the relevant evidence
21 report, with reference to issues regarding the plausibility of the estimate or to factors
22 set out in NICE methods manuals⁴.

23 When QALYs or life years gained are not used in the analysis, results are difficult to
24 interpret unless one strategy dominates the others with respect to every relevant
25 health outcome and cost.

26 **2.7.4 In the absence of health economic evidence**

27 When no relevant published health economic studies were found, and a new analysis
28 was not prioritised, the committee made a qualitative judgement about cost
29 effectiveness by considering expected differences in resource use between options
30 and relevant UK NHS unit costs, alongside the results of the review of clinical
31 effectiveness evidence.

32 The UK NHS costs reported in the guideline are those that were presented to the
33 committee and were correct at the time recommendations were drafted. They may
34 have changed subsequently before the time of publication. However, we have no
35 reason to believe they have changed substantially.

36 **2.8 Developing recommendations**

37 Over the course of the guideline development process, the committee was presented
38 with:

- 39 • Summaries of clinical and health economic evidence and quality (as presented in
40 evidence reports A–R).

- 1 • Evidence tables of the clinical and health economic evidence reviewed from the
2 literature. All evidence tables can be found in appendices to the relevant evidence
3 reports.
- 4 • Forest plots (in appendices to the relevant evidence reports).
- 5 • A description of the methods and results of the cost-effectiveness analysis
6 undertaken for the guideline (in a separate economic analysis report).

7 Decisions on whether a recommendation could be made, and if so in which direction,
8 were made on the basis of the committee's interpretation of the available evidence,
9 taking into account the balance of benefits, harms and costs between different
10 courses of action. This was either done formally in an economic model, or informally.
11 The net clinical benefit over harm (clinical effectiveness) was considered, focusing on
12 the magnitude of the effect (or clinical importance), quality of evidence (including the
13 uncertainty) and amount of evidence available. When this was done informally, the
14 committee took into account the clinical benefits and harms when one intervention
15 was compared with another. The assessment of net clinical benefit was moderated
16 by the importance placed on the outcomes (the committee's values and preferences),
17 and the confidence the committee had in the evidence (evidence quality). Secondly,
18 the committee assessed whether the net clinical benefit justified any differences in
19 costs between the alternative interventions. When the clinical harms were judged by
20 the committee to outweigh any clinical benefits, they considered making a
21 recommendation not to offer an intervention. This was dependant on whether the
22 intervention had any reasonable prospect of providing cost-effective benefits to
23 people using services and whether stopping the intervention was likely to cause harm
24 for people already receiving it.

25 When clinical and health economic evidence was of poor quality, conflicting or
26 absent, the committee decided on whether a recommendation could be made based
27 on its expert opinion. The considerations for making consensus-based
28 recommendations include the balance between potential harms and benefits, the
29 economic costs compared to the economic benefits, current practices,
30 recommendations made in other relevant guidelines, patient preferences and equality
31 issues. The consensus recommendations were agreed through discussions in the
32 committee. The committee also considered whether the uncertainty was sufficient to
33 justify delaying making a recommendation to await further research, taking into
34 account the potential harm of failing to make a clear recommendation (see
35 section 2.8.1 below).

36 The committee considered the appropriate 'strength' of each recommendation. This
37 takes into account the quality of the evidence but is conceptually different. Some
38 recommendations are 'strong' in that the committee believes that the vast majority of
39 healthcare and other professionals and patients would choose a particular
40 intervention if they considered the evidence in the same way that the committee has.
41 This is generally the case if the benefits clearly outweigh the harms for most people
42 and the intervention is likely to be cost effective. However, there is often a closer
43 balance between benefits and harms, and some patients would not choose an
44 intervention whereas others would. This may happen, for example, if some patients
45 are particularly averse to some side effect and others are not. In these circumstances
46 the recommendation is generally weaker, although it may be possible to make
47 stronger recommendations about specific groups of patients.

48 The committee focused on the following factors in agreeing the wording of the
49 recommendations:

- 1 • The actions health professionals need to take.
2 • The information readers need to know.
3 • The strength of the recommendation (for example the word ‘offer’ was used for
4 strong recommendations and ‘consider’ for weaker recommendations).
5 • The involvement of patients (and their carers if needed) in decisions on treatment
6 and care.
7 • Consistency with NICE’s standard advice on recommendations about drugs,
8 waiting times and ineffective interventions (see section 9.2 in the NICE guidelines
9 manual⁵).

10 The main considerations specific to each recommendation are outlined in ‘The
11 committee’s discussion of the evidence’ section within each evidence report.

12 **2.8.1 Research recommendations**

13 When areas were identified for which good evidence was lacking, the committee
14 considered making recommendations for future research. Decisions about the
15 inclusion of a research recommendation were based on factors such as:

- 16 • the importance to patients or the population
17 • national priorities
18 • potential impact on the NHS and future NICE guidance
19 • ethical and technical feasibility.

20 **2.8.2 Validation process**

21 This guidance is subject to a 6-week public consultation and feedback as part of the
22 quality assurance and peer review of the document. All comments received from
23 registered stakeholders are responded to in turn and posted on the NICE website.

24 **2.8.3 Updating the guideline**

25 Following publication, and in accordance with the NICE guidelines manual, NICE will
26 undertake a review of whether the evidence base has progressed significantly to alter
27 the guideline recommendations and warrant an update.

28 **2.8.4 Disclaimer**

29 Healthcare providers need to use clinical judgement, knowledge and expertise when
30 deciding whether it is appropriate to apply guidelines. The recommendations cited
31 here are a guide and may not be appropriate for use in all situations. The decision to
32 adopt any of the recommendations cited here must be made by practitioners in light
33 of individual patient circumstances, the wishes of the patient, clinical expertise and
34 resources.

35 The National Guideline Centre disclaims any responsibility for damages arising out of
36 the use or non-use of this guideline and the literature used in support of this
37 guideline.

1 2.8.5 Funding

2 The National Guideline Centre was commissioned by the National Institute for Health
3 and Care Excellence to undertake the work on this guideline.

4

5 2.9 Guideline-specific terms

Term	Definition
Active Surveillance	When a patient is kept under active surveillance they are neither actively treated nor discharged, but instead kept under regular monitoring (for example, by annual follow up) to assess for progression or recurrence.
Anaplastic Thyroid Cancer	A rare and poorly differentiated form of thyroid cancer.
Contrast Enhanced Ultrasound	Contrast enhanced ultrasound (CEUS) involves the injection of a contrast agent into the circulation. The contrast agent comprises gas filled microbubbles that have a much greater echogenicity than surrounding tissue, and it is therefore potentially superior to Doppler US for detection of microvascular perfusion in nodules. There is some evidence that hypo-enhancement combined with heterogenous enhancement has diagnostic potential.
Central Neck Dissection	Central neck dissection involves the surgical removal of central lymph nodes, either prophylactically or in response to tumour cell invasion.
Differentiated Thyroid Cancer	Differentiated thyroid cancer includes papillary, follicular and Hurthle Cell thyroid cancer.
Dipyridamole/technetium sestamibi scans (more commonly known as MIBI scans, an acronym for methoxyisobutyl isonitrile)	Dipyridamole/technetium sestamibi scans (more commonly known as MIBI scans, an acronym for methoxyisobutyl isonitrile) are a type of radioisotope scan used in the diagnostic evaluation of thyroid nodules with nondiagnostic cytology.
Doppler Ultrasound	Doppler ultrasound uses detection of the doppler effect (a frequency shift upwards with approaching structures and a frequency shift downwards with receding structures) to detect movement of blood, and can therefore detect the presence of vascularity. Vascularity is thought to be increased in malignant nodules, which suggests a basis for diagnostic testing.
Dynamic risk stratification	Dynamic risk stratification is used to stratify risk groups to optimise ongoing management post RAI. Low risk groups have excellent prognosis with low-risk relapse and can have more relaxed follow up and probable earlier discharge. Intermediate/high risk need more careful and longer term follow up due to expected high risk of recurrence.
Elastography	Elastography is a newer technique for evaluation of thyroid nodules that utilises the fact that malignant nodules are often stiffer than benign structures. Real time elastography (RTE) involves the

Term	Definition
	ultrasonographer applying a set level of compression over the nodule (measured by the software) and then evaluating the strain on the nodular tissue, this strain being proportional to stiffness. This can be coded by colour on the ultrasound display, and various diagnostic scales exist that classify the stiffness of the nodule by the colours displayed. If the strain is directly measured and then compared to the strain in the surrounding normal tissues, strain ratios can be produced, which may also have a diagnostic potential. In contrast, shear wave elastography (SWE) involves measurement of the elasticity of the nodule by propagating a force impulse. This produces shear waves in the tissue, and their velocity can be measured. The velocity of the shear wave is proportional to stiffness, and the Young's modulus (Elasticity Index) can be calculated.
External Beam Radiation	External Beam Radiation may be given as an adjuvant treatment in people who may not have responded well to surgery, or who may not be suitable for radioactive iodine ablation.
Extra Thyroidal Extension	Extrathyroidal extension (ETE) involves extension of the primary tumour beyond the thyroid capsule into the surrounding tissues, such as the trachea, larynx, oesophagus, and recurrent laryngeal nerve).
Fine Needle Aspiration Cytology	Fine needle aspiration cytology involves the removal of cells from a nodule via a small needle. This is a central process during diagnosis of thyroid malignancy.
Grey-scale Ultrasound	<i>see Ultrasound</i>
Highly sensitive thyroglobulin assays	Very small amounts of thyroglobulin in serum may be undetectable by standard assays, but highly sensitive assays have been developed that can detect them at levels as low as 0.2 micrograms per litre
Positron Emission Tomography	A PET scan produces highly detailed 3D images of the interior of the body. These can be combined with CT or MRI to produce images of even greater resolution.
Hemithyroidectomy	Surgical removal of one lobe of the thyroid, leaving the contralateral lobe in-situ.
Isthmusectomy	Thyroid isthmusectomy is a surgical procedure that only removes the thyroid isthmus. The isthmus is a small band of tissue that bridges the 2 lobes of the thyroid gland and passes anterior to the trachea.
Lateral Node	Lateral nodes are located in the lateral wall of the axilla.
Levothyroxine (L-T4)	Levothyroxine, also known as L-T4, is a synthetic form of thyroxine (T4). It is used for supplementation of thyroid hormone after thyroidectomy or other causes of hypothyroidism
Liothyronine (L-T3)	Liothyronine, also known as L-T3, is a synthetic form of triiodothyronine (T3). It is used for

Term	Definition
	supplementation of thyroid hormone after thyroidectomy or other causes of hypothyroidism.
Lobectomy	See <i>hemithyroidectomy</i>
Magnetic Resonance imaging	MRI uses magnetic fields and radio waves to create high resolution images of the interior of the body.
Medullary Thyroid Cancer	This is a rarer type of thyroid cancer than differentiated thyroid cancer. About 25% of medullary cancers are inherited.
Molecular testing	Molecular testing evaluates nodule samples at the molecular level. For example, it can look at characteristics of RNA or DNA molecules, which may have the potential to differentiate benign and malignant cells in people who are indeterminate on cytological testing.
Papillary microcarcinoma	Papillary carcinoma of the thyroid that is less than 10 mm in diameter.
Radioactive Iodine Ablation	Radioactive iodine (RAI) ablation uses radiation from iodine-131 to destroy thyroid tissue. The radioactive iodine is taken in capsule form to ablate any remaining thyroid tissue post-surgery. Iodine uptake can be stimulated by limiting dietary iodine for a period of time prior to ablation. For other methods to encourage radioactive iodine uptake by thyroid tissue see <i>Thyroid Stimulating Hormone</i> .
Radioactive Iodine Treatment	Radioactive iodine (RAI) treatment uses radiation from iodine-131 to destroy thyroid cancer that has recurred after treatment, such as after surgery or a previous course of RAI ablation. The radioactive iodine is taken in capsule form. Iodine uptake can be stimulated by limiting dietary iodine for a period of time prior to treatment. For other methods to encourage radioactive iodine uptake by thyroid tissue see <i>Thyroid Stimulating Hormone</i> .
Rapid On-Site Assessment	FNAC can involve non-diagnostic readings, which is very often due to an insufficient number of cells being harvested. If this is only discovered when the sample is returned to the laboratory this can cause delays, as the patient will need to be recalled for further testing. Rapid on-site assessment is a method that attempts to avoid such delay by checking samples for adequacy at the time of removal from the nodule 'at the bedside'.
Real Time Elastography	See elastography
Recombinant TSH	Often abbreviated to rh TSH, recombinant TSH is an artificial form of thyroid stimulating hormone sometimes prescribed to optimise radioactive iodine uptake by thyroid cells. See <i>Thyroid Stimulating Hormone</i>
Shear Wave Elastography	See elastography
Stimulated thyroglobulin	Very small amounts of thyroglobulin in serum may be undetectable by standard assays, but these may be made detectable after stimulation of any remaining thyroid cells by TSH. TSH levels can be raised by rh TSH supplementation or thyroid hormone withdrawal.

Term	Definition
Thyroglobulin	Thyroglobulin is a protein manufactured by thyroid follicular cells. It is therefore a marker for the continued presence of thyroid cells in the body.
Thyroglobulin antibodies	Thyroglobulin antibodies are present in some people, but not all. When present they may tend to reduce the levels of thyroglobulin present in the body. Therefore, when thyroglobulin antibodies are detected, this will influence interpretation of measured thyroglobulin levels. For example, an undetectable level of thyroglobulin cannot be used to rule out the presence of thyroid cells if thyroglobulin antibodies have been detected.
Thyrotrophin alpha	Recombinant thyroid stimulating hormone (rh TSH). See Thyroid Stimulating Hormone.
Thyrogen	Thyrogen is the trade name for thyrotrophin alpha, or recombinant thyroid stimulating hormone (rh TSH). See Thyroid Stimulating Hormone.
THYroid CANcer-Quality of Life scale	A thyroid-specific quality of life scale
Thyroid Imaging Reporting and Data System	The TIRADS risk stratification system categorises nodules according to US findings, which facilitates decisions on further management. They are often based on a five or six point scale, with higher scores denoting a higher risk of malignancy. There are several TIRADS systems in use, such as the EU-TIRADS, ACR-TIRADS, and Kwak TIRADS, all using different criteria.
Tumour (T), nodes (N) and metastases (M)	The TNM cancer staging system is used for many different types of cancer, and gives information about the size and extent of the main tumour (T), the number of nearby nodes that have cancer (N) and whether the cancer has metastasised (M).
Thyroid Hormone Withdrawal	The withdrawal of thyroid hormone supplementation may stimulate Thyroid Stimulating Hormone production and thereby increase the amount of iodine taken up by thyroid cells during radioactive iodine treatment. The effects of thyroid hormone withdrawal on the patient may depend on the duration of withdrawal. If Levothyroxine (L-T4) is being withdrawn, withdrawal usually needs to occur for 4-6 weeks for TSH levels to increase sufficiently, whereas if Liothyronine (L-T3) is being withdrawn the withdrawal period may be shorter. See <i>Thyroid Stimulating Hormone</i> .
Thyroid peroxidase antibody test	Thyroid peroxidase is an enzyme that is usually present in thyroid tissue. A thyroid peroxidase antibody test detects antibodies towards thyroid peroxidase. The presence of such antibodies can suggest autoimmune disorders, which may assist in the interpretation of cytopathology.
Thyroid Stimulating Hormone	Thyroid Stimulating Hormone (TSH) is secreted by the pituitary gland to stimulate the production of thyroxin when thyroxin levels drop. TSH may be useful prior to radioactive iodine (RAI) treatment or ablation because it promotes iodine uptake by thyroid cells as part of its action to stimulate the production of thyroxin. High levels of TSH can

Term	Definition
	therefore optimise the amounts of radioactive iodine reaching thyroid tissue, and TSH thus has the potential to increase efficacy of radioactive iodine treatment. High levels of TSH are accomplished by either withdrawing supplemental thyroxine (or supplemental liothyronine) or by giving recombinant TSH (rh TSH) prior to RAI. On the other hand, after any RAI treatment is over, suppression of TSH levels may be encouraged in certain groups of patients because it is believed that TSH may promote recurrence or progression of thyroid cancer in the longer term.
Total Thyroidectomy	The surgical removal of the entire thyroid gland.
Ultrasound	Grey scale ultrasound uses a probe which emits sound waves at a frequency between 5 and 15 MHz. These sound waves pass through the nodule until they reach a boundary between different tissues (such as calcified and non-calcified tissue), where some are reflected back to the apparatus and some travel on to the next boundary. The structures at each boundary will have different sound wave reflection properties, and these distinct properties are captured by the amplitude of the reflected sound waves detected by the apparatus. In addition, the depth of each boundary within the tissue can be captured by the timing of return of the reflected sound waves. Therefore, it is possible to build up an accurate picture of the location of different nodular structures in space, each structure differentiated from others by their different acoustic properties, which are coded by different tones of grey. Certain grey-scale characteristics have been shown to be associated with malignancy and so have a basis in diagnostic testing.

1

2.10 General terms

3

Term	Definition
Abstract	Summary of a study, which may be published alone or as an introduction to a full scientific paper.
Algorithm (in guidelines)	A flow chart of the clinical decision pathway described in the guideline, where decision points are represented with boxes, linked with arrows.
Allocation concealment	The process used to prevent advance knowledge of group assignment in an RCT. The allocation process should be impervious to any influence by the individual making the allocation, by being administered by someone who is not responsible for recruiting participants.
Applicability	How well the results of a study or NICE evidence review can answer a clinical question or be applied to the population being considered.

Term	Definition
Arm (of a clinical study)	Subsection of individuals within a study who receive one particular intervention, for example placebo arm.
Association	Statistical relationship between 2 or more events, characteristics or other variables. The relationship may or may not be causal.
Base case analysis	In an economic evaluation, this is the main analysis based on the most plausible estimate of each input. In contrast, see Sensitivity analysis.
Baseline	The initial set of measurements at the beginning of a study (after run-in period where applicable), with which subsequent results are compared.
Bayesian analysis	A method of statistics, where a statistic is estimated by combining established information or belief (the 'prior') with new evidence (the 'likelihood') to give a revised estimate (the 'posterior').
Before-and-after study	A study that investigates the effects of an intervention by measuring particular characteristics of a population both before and after taking the intervention, and assessing any change that occurs.
Bias	Influences on a study that can make the results look better or worse than they really are. (Bias can even make it look as if a treatment works when it does not.) Bias can occur by chance, deliberately or as a result of systematic errors in the design and execution of a study. It can also occur at different stages in the research process, for example, during the collection, analysis, interpretation, publication or review of research data. For examples see selection bias, performance bias, information bias, confounding factor, and publication bias.
Blinding	<p>A way to prevent researchers, doctors and patients in a clinical trial from knowing which study group each patient is in so they cannot influence the results. The best way to do this is by sorting patients into study groups randomly. The purpose of 'blinding' or 'masking' is to protect against bias.</p> <p>A single-blinded study is one in which patients do not know which study group they are in (for example whether they are taking the experimental drug or a placebo). A double-blinded study is one in which neither patients nor the researchers and doctors know which study group the patients are in. A triple blind study is one in which neither the patients, clinicians or the people carrying out the statistical analysis know which treatment patients received.</p>
C statistic	The area under a receiver operated characteristic (ROC) curve, which provides an integrated measure of accuracy (sensitivity and specificity) at the full range of test thresholds. See <i>Receiver operated characteristic (ROC) curve</i>
Calibration	<p>In a general sense this refers to the definition of values of a measure using the values derived from a gold standard method applied to the same object of measurement.</p> <p>In the context of this guideline, calibration refers to the plotting of observed risks of an outcome against predicted risks derived from a prediction test. Good calibration will lead to a straight line that is close to the line extending at 45 degrees from the origin. This indicates that the test is able to accurately predict the actual risks.</p>
Carer (caregiver)	Someone who looks after family, partners or friends in need of help because they are ill, frail or have a disability.
Case-control study	A study to find out the cause(s) of a disease or condition. This is done by comparing a group of patients who have the disease or condition

Term	Definition
	<p>(cases) with a group of people who do not have it (controls) but who are otherwise as similar as possible (in characteristics thought to be unrelated to the causes of the disease or condition). This means the researcher can look for aspects of their lives that differ to see if they may cause the condition.</p> <p>For example, a group of people with lung cancer might be compared with a group of people the same age that do not have lung cancer. The researcher could compare how long both groups had been exposed to tobacco smoke. Such studies are retrospective because they look back in time from the outcome to the possible causes of a disease or condition.</p>
Case series	Report of a number of cases of a given disease, usually covering the course of the disease and the response to treatment. There is no comparison (control) group of patients.
Clinical efficacy	The extent to which an intervention is active when studied under controlled research conditions.
Clinical effectiveness	<p>How well a specific test or treatment works when used in the 'real world' (for example, when used by a doctor with a patient at home), rather than in a carefully controlled clinical trial. Trials that assess clinical effectiveness are sometimes called management trials.</p> <p>Clinical effectiveness is not the same as efficacy.</p>
Clinician	A healthcare professional who provides patient care. For example, a doctor, nurse or physiotherapist.
Cochrane Review	The Cochrane Library consists of a regularly updated collection of evidence-based medicine databases including the Cochrane Database of Systematic Reviews (reviews of randomised controlled trials prepared by the Cochrane Collaboration).
Cohort study	A study with 2 or more groups of people – cohorts – with similar characteristics. One group receives a treatment, is exposed to a risk factor or has a particular symptom and the other group does not. The study follows their progress over time and records what happens. See also observational study.
Comorbidity	A disease or condition that someone has in addition to the health problem being studied or treated.
Comparability	Similarity of the groups in characteristics likely to affect the study results (such as health status or age).
Concordance	This is a recent term whose meaning has changed. It was initially applied to the consultation process in which doctor and patient agree therapeutic decisions that incorporate their respective views, but now includes patient support in medicine taking as well as prescribing communication. Concordance reflects social values but does not address medicine-taking and may not lead to improved adherence.
Confidence interval (CI)	A range of values for an unknown population parameter with a stated 'confidence' (conventionally 95%) that it contains the true value. The interval is calculated from sample data, and generally straddles the sample estimate. The 'confidence' value means that if the method used to calculate the interval is repeated many times, then that proportion of intervals will actually contain the true value.
Confounding factor	Something that influences a study and can result in misleading findings if it is not understood or appropriately dealt with.

Term	Definition
	For example, a study of heart disease may look at a group of people that exercises regularly and a group that does not exercise. If the ages of the people in the 2 groups are different, then any difference in heart disease rates between the 2 groups could be because of age rather than exercise. Therefore age is a confounding factor.
Consensus methods	Techniques used to reach agreement on a particular issue. Consensus methods may be used to develop NICE guidance if there is not enough good quality research evidence to give a clear answer to a question. Formal consensus methods include Delphi and nominal group techniques.
Control group	A group of people in a study who do not receive the treatment or test being studied. Instead, they may receive the standard treatment (sometimes called 'usual care') or a dummy treatment (placebo). The results for the control group are compared with those for a group receiving the treatment being tested. The aim is to check for any differences. Ideally, the people in the control group should be as similar as possible to those in the treatment group, to make it as easy as possible to detect any effects due to the treatment.
Cost–benefit analysis (CBA)	Cost–benefit analysis is one of the tools used to carry out an economic evaluation. The costs and benefits are measured using the same monetary units (for example, pounds sterling) to see whether the benefits exceed the costs.
Cost–consequences analysis (CCA)	Cost–consequences analysis is one of the tools used to carry out an economic evaluation. This compares the costs (such as treatment and hospital care) and the consequences (such as health outcomes) of a test or treatment with a suitable alternative. Unlike cost–benefit analysis or cost-effectiveness analysis, it does not attempt to summarise outcomes in a single measure (like the quality-adjusted life year) or in financial terms. Instead, outcomes are shown in their natural units (some of which may be monetary) and it is left to decision-makers to determine whether, overall, the treatment is worth carrying out.
Cost-effectiveness analysis (CEA)	Cost-effectiveness analysis is one of the tools used to carry out an economic evaluation. The benefits are expressed in non-monetary terms related to health, such as symptom-free days, heart attacks avoided, deaths avoided or life years gained (that is, the number of years by which life is extended as a result of the intervention).
Cost-effectiveness model	An explicit mathematical framework, which is used to represent clinical decision problems and incorporate evidence from a variety of sources in order to estimate the costs and health outcomes.
Cost–utility analysis (CUA)	Cost–utility analysis is one of the tools used to carry out an economic evaluation. The benefits are assessed in terms of both quality and duration of life, and expressed as quality-adjusted life years (QALYs). See also utility.
Credible interval (CrI)	The Bayesian equivalent of a confidence interval.
Decision analysis	An explicit quantitative approach to decision-making under uncertainty, based on evidence from research. This evidence is translated into probabilities, and then into diagrams or decision trees which direct the clinician through a succession of possible scenarios, actions and outcomes.
Deterministic analysis	In economic evaluation, this is an analysis that uses a point estimate for each input. In contrast, see Probabilistic analysis

Term	Definition
Diagnostic odds ratio	The diagnostic odds ratio is a measure of the effectiveness of a diagnostic test. It is defined as the ratio of the odds of the test being positive if the subject has a disease relative to the odds of the test being positive if the subject does not have the disease.
Discounting	Costs and perhaps benefits incurred today have a higher value than costs and benefits occurring in the future. Discounting health benefits reflects individual preference for benefits to be experienced in the present rather than the future. Discounting costs reflects individual preference for costs to be experienced in the future rather than the present.
Disutility	The loss of quality of life associated with having a disease or condition. See Utility
Dominance	A health economics term. When comparing tests or treatments, an option that is both less effective and costs more is said to be 'dominated' by the alternative.
Drop-out	A participant who withdraws from a trial before the end.
Economic evaluation	An economic evaluation is used to assess the cost effectiveness of healthcare interventions (that is, to compare the costs and benefits of a healthcare intervention to assess whether it is worth doing). The aim of an economic evaluation is to maximise the level of benefits – health effects – relative to the resources available. It should be used to inform and support the decision-making process; it is not supposed to replace the judgement of healthcare professionals. There are several types of economic evaluation: cost–benefit analysis, cost–consequences analysis, cost-effectiveness analysis, cost-minimisation analysis and cost–utility analysis. They use similar methods to define and evaluate costs, but differ in the way they estimate the benefits of a particular drug, programme or intervention.
Effect (as in effect measure, treatment effect, estimate of effect, effect size)	A measure that shows the magnitude of the outcome in one group compared with that in a control group. For example, if the absolute risk reduction is shown to be 5% and it is the outcome of interest, the effect size is 5%. The effect size is usually tested, using statistics, to find out how likely it is that the effect is a result of the treatment and has not just happened by chance (that is, to see if it is statistically significant).
Effectiveness	How beneficial a test or treatment is under usual or everyday conditions, compared with doing nothing or opting for another type of care.
Efficacy	How beneficial a test, treatment or public health intervention is under ideal conditions (for example, in a laboratory), compared with doing nothing or opting for another type of care.
Epidemiological study	The study of a disease within a population, defining its incidence and prevalence and examining the roles of external influences (for example, infection, diet) and interventions.
EQ-5D (EuroQol 5 dimensions)	A standardised instrument used to measure health-related quality of life. It provides a single index value for health status.
Evidence	Information on which a decision or guidance is based. Evidence is obtained from a range of sources including randomised controlled trials, observational studies, expert opinion (of clinical professionals or patients).
Exclusion criteria (literature review)	Explicit standards used to decide which studies should be excluded from consideration as potential sources of evidence.

Term	Definition
Exclusion criteria (clinical study)	Criteria that define who is not eligible to participate in a clinical study.
Extended dominance	If Option A is both more clinically effective than Option B and has a lower cost per unit of effect, when both are compared with a do-nothing alternative then Option A is said to have extended dominance over Option B. Option A is therefore cost effective and should be preferred, other things remaining equal.
Extrapolation	An assumption that the results of studies of a specific population will also hold true for another population with similar characteristics.
Follow-up	Observation over a period of time of an individual, group or initially defined population whose appropriate characteristics have been assessed in order to observe changes in health status or health-related variables.
Generalisability	The extent to which the results of a study hold true for groups that did not participate in the research. See also external validity.
Gold standard	A method, procedure or measurement that is widely accepted as being the best available to test for or treat a disease.
GRADE, GRADE profile	A system developed by the GRADE Working Group to address the shortcomings of present grading systems in healthcare. The GRADE system uses a common, sensible and transparent approach to grading the quality of evidence. The results of applying the GRADE system to clinical trial data are displayed in a table known as a GRADE profile.
Harms	Adverse effects of an intervention.
Hazard Ratio	The hazard or chance of an event occurring in the treatment arm of a study as a ratio of the chance of an event occurring in the control arm over time.
Health economics	Study or analysis of the cost of using and distributing healthcare resources.
Health-related quality of life (HRQoL)	A measure of the effects of an illness to see how it affects someone's day-to-day life.
Heterogeneity or Lack of homogeneity	The term is used in meta-analyses and systematic reviews to describe when the results of a test or treatment (or estimates of its effect) differ significantly in different studies. Such differences may occur as a result of differences in the populations studied, the outcome measures used or because of different definitions of the variables involved. It is the opposite of homogeneity.
Imprecision	Results are imprecise when studies include relatively few patients and few events and thus have wide confidence intervals around the estimate of effect.
Inclusion criteria (literature review)	Explicit criteria used to decide which studies should be considered as potential sources of evidence.
Incremental analysis	The analysis of additional costs and additional clinical outcomes with different interventions.
Incremental cost	The extra cost linked to using one test or treatment rather than another. Or the additional cost of doing a test or providing a treatment more frequently.
Incremental cost-effectiveness ratio (ICER)	The difference in the mean costs in the population of interest divided by the differences in the mean outcomes in the population of interest for one treatment compared with another.
Incremental net benefit (INB)	The value (usually in monetary terms) of an intervention net of its cost compared with a comparator intervention. The INB can be calculated

Term	Definition
	for a given cost-effectiveness (willingness to pay) threshold. If the threshold is £20,000 per QALY gained then the INB is calculated as: $(£20,000 \times \text{QALYs gained}) - \text{Incremental cost}$.
Indirectness	The available evidence is different to the review question being addressed, in terms of PICO (population, intervention, comparison and outcome).
Intention-to-treat analysis (ITT)	An assessment of the people taking part in a clinical trial, based on the group they were initially (and randomly) allocated to. This is regardless of whether or not they dropped out, fully complied with the treatment or switched to an alternative treatment. Intention-to-treat analyses are often used to assess clinical effectiveness because they mirror actual practice: that is, not everyone complies with treatment and the treatment people receive may be changed according to how they respond to it.
Intervention	In medical terms this could be a drug treatment, surgical procedure, diagnostic or psychological therapy. Examples of public health interventions could include action to help someone to be physically active or to eat a more healthy diet.
Intraoperative	The period of time during a surgical procedure.
Kappa statistic	A statistical measure of inter-rater agreement that takes into account the agreement occurring by chance.
Length of stay	The total number of days a participant stays in hospital.
Licence	See 'Product licence'.
Life years gained	Mean average years of life gained per person as a result of the intervention compared with an alternative intervention.
Likelihood ratio	The likelihood ratio combines information about the sensitivity and specificity. It tells you how much a positive or negative result changes the likelihood that a patient would have the disease. The likelihood ratio of a positive test result (LR+) is sensitivity divided by (1 minus specificity).
Long-term care	Residential care in a home that may include skilled nursing care and help with everyday activities. This includes nursing homes and residential homes.
Logistic regression or Logit model	In statistics, logistic regression is a type of analysis used for predicting the outcome of a binary dependent variable based on one or more predictor variables. It can be used to estimate the log of the odds (known as the 'logit').
Loss to follow-up	A patient, or the proportion of patients, actively participating in a clinical trial at the beginning, but whom the researchers were unable to trace or contact by the point of follow-up in the trial
Markov model	A method for estimating long-term costs and effects for recurrent or chronic conditions, based on health states and the probability of transition between them within a given time period (cycle).
Meta-analysis	A method often used in systematic reviews. Results from several studies of the same test or treatment are combined to estimate the overall effect of the treatment.
Multivariate model	A statistical model for analysis of the relationship between 2 or more predictor (independent) variables and the outcome (dependent) variable.
Negative predictive value (NPV)	In screening or diagnostic tests: A measure of the usefulness of a screening or diagnostic test. It is the proportion of those with a

Term	Definition
	negative test result who do not have the disease, and can be interpreted as the probability that a negative test result is correct. It is calculated as follows: $TN/(TN+FN)$
Net monetary benefit (NMB)	The value in monetary terms of an intervention net of its cost. The NMB can be calculated for a given cost-effectiveness threshold. If the threshold is £20,000 per QALY gained then the NMB for an intervention is calculated as: $(£20,000 \times \text{mean QALYs}) - \text{mean cost}$. The most preferable option (that is, the most clinically effective option to have an ICER below the threshold selected) will be the treatment with the highest NMB.
Non-randomised intervention study	A quantitative study investigating the effectiveness of an intervention that does not use randomisation to allocate patients (or units) to treatment groups. Non-randomised studies include observational studies, where allocation to groups occurs through usual treatment decisions or people's preferences. Non-randomised studies can also be experimental, where the investigator has some degree of control over the allocation of treatments. Non-randomised intervention studies can use a number of different study designs, and include cohort studies, case-control studies, controlled before-and-after studies, interrupted-time-series studies and quasi-randomised controlled trials.
Number needed to treat (NNT)	The average number of patients who need to be treated to get a positive outcome. For example, if the NNT is 4, then 4 patients would have to be treated to ensure 1 of them gets better. The closer the NNT is to 1, the better the treatment. For example, if you give a stroke prevention drug to 20 people before 1 stroke is prevented, the number needed to treat is 20. See also number needed to harm, absolute risk reduction.
Observational study	Individuals or groups are observed or certain factors are measured. No attempt is made to affect the outcome. For example, an observational study of a disease or treatment would allow 'nature' or usual medical care to take its course. Changes or differences in one characteristic (for example, whether or not people received a specific treatment or intervention) are studied without intervening. There is a greater risk of selection bias than in experimental studies.
Odds ratio	A measure of treatment effectiveness. The odds of an event happening in the treatment group, expressed as a proportion of the odds of it happening in the control group. The 'odds' is the ratio of events to non-events.
Opportunity cost	The loss of other healthcare programmes displaced by investment in or introduction of another intervention. This may be best measured by the health benefits that could have been achieved had the money been spent on the next best alternative healthcare intervention.
Outcome	The impact that a test, treatment, policy, programme or other intervention has on a person, group or population. Outcomes from interventions to improve the public's health could include changes in knowledge and behaviour related to health, societal changes (for example, a reduction in crime rates) and a change in people's health and wellbeing or health status. In clinical terms, outcomes could include the number of patients who fully recover from an illness or the number of hospital admissions, and an improvement or deterioration in someone's health, functional ability, symptoms or situation. Researchers should decide what outcomes to measure before a study begins.

Term	Definition
P value	<p>The p value is a statistical measure that indicates whether or not an effect is statistically significant.</p> <p>For example, if a study comparing 2 treatments found that one seems more effective than the other, the p value is the probability of obtaining these, or more extreme results by chance. By convention, if the p value is below 0.05 (that is, there is less than a 5% probability that the results occurred by chance) it is considered that there probably is a real difference between treatments. If the p value is 0.001 or less (less than a 1% probability that the results occurred by chance), the result is seen as highly significant.</p> <p>If the p value shows that there is likely to be a difference between treatments, the confidence interval describes how big the difference in effect might be.</p>
Perform	<p>Performance bias results from systematic differences in the way that patients from each group are cared for and treated during the intervention phase of a trial, over and above the intrinsic differences relating to the actual treatments themselves. For example one group may experience more contact, more senior nursing care, or more vigilant monitoring. It also refers to differences in patient beliefs across groups about the efficacy of treatment. Both of these differences can influence outcome and thus cause bias. Blinding of healthcare professional and patients can help to reduce such bias.</p>
Perioperative	<p>The period from admission through surgery until discharge, encompassing the preoperative and postoperative periods.</p>
Placebo	<p>A fake (or dummy) treatment given to participants in the control group of a clinical trial. It is indistinguishable from the actual treatment (which is given to participants in the experimental group). The aim is to determine what effect the experimental treatment has had – over and above any placebo effect caused because someone has received (or thinks they have received) care or attention.</p>
Polypharmacy	<p>The use or prescription of multiple medications.</p>
Posterior distribution	<p>In Bayesian statistics this is the probability distribution for a statistic based after combining established information or belief (the prior) with new evidence (the likelihood).</p>
Positive predictive value (PPV)	<p>In screening or diagnostic tests: A measure of the usefulness of a screening or diagnostic test. It is the proportion of those with a positive test result who have the disease, and can be interpreted as the probability that a positive test result is correct. It is calculated as follows: $TP/(TP+FP)$</p>
Postoperative	<p>Pertaining to the period after patients leave the operating theatre, following surgery.</p>
Post-test probability	<p>In diagnostic tests: The proportion of patients with that particular test result who have the target disorder (post-test odds/[1 plus post-test odds]).</p>
Power (statistical)	<p>The ability to demonstrate an association when one exists. Power is related to sample size; the larger the sample size, the greater the power and the lower the risk that a possible association could be missed.</p>
Preoperative	<p>The period before surgery commences.</p>
Pre-test probability	<p>In diagnostic tests: The proportion of people with the target disorder in the population at risk at a specific time point or time interval. Prevalence may depend on how a disorder is diagnosed.</p>

Term	Definition
Prevalence	See Pre-test probability.
Prior distribution	In Bayesian statistics this is the probability distribution for a statistic based on previous evidence or belief.
Primary care	Healthcare delivered outside hospitals. It includes a range of services provided by GPs, nurses, health visitors, midwives and other healthcare professionals and allied health professionals such as dentists, pharmacists and opticians.
Primary outcome	The outcome of greatest importance, usually the one in a study that the power calculation is based on.
Probabilistic analysis	In economic evaluation, this is an analysis that uses a probability distribution for each input. In contrast, see Deterministic analysis.
Product licence	An authorisation from the MHRA to market a medicinal product.
Prognosis	A probable course or outcome of a disease. Prognostic factors are patient or disease characteristics that influence the course. Good prognosis is associated with low rate of undesirable outcomes; poor prognosis is associated with a high rate of undesirable outcomes.
Prospective study	A research study in which the health or other characteristic of participants is monitored (or 'followed up') for a period of time, with events recorded as they happen. This contrasts with retrospective studies.
Publication bias	Publication bias occurs when researchers publish the results of studies showing that a treatment works well and don't publish those showing it did not have any effect. If this happens, analysis of the published results will not give an accurate idea of how well the treatment works. This type of bias can be assessed by a funnel plot.
Quality of life	See 'Health-related quality of life'.
Quality-adjusted life year (QALY)	A measure of the state of health of a person or group in which the benefits, in terms of length of life, are adjusted to reflect the quality of life. One QALY is equal to 1 year of life in perfect health. QALYS are calculated by estimating the years of life remaining for a patient following a particular treatment or intervention and weighting each year with a quality of life score (on a scale of 0 to 1). It is often measured in terms of the person's ability to perform the activities of daily life, freedom from pain and mental disturbance.
Randomisation	Assigning participants in a research study to different groups without taking any similarities or differences between them into account. For example, it could involve using a random numbers table or a computer-generated random sequence. It means that each individual (or each group in the case of cluster randomisation) has the same chance of receiving each intervention.
Randomised controlled trial (RCT)	A study in which a number of similar people are randomly assigned to 2 (or more) groups to test a specific drug or treatment. One group (the experimental group) receives the treatment being tested, the other (the comparison or control group) receives an alternative treatment, a dummy treatment (placebo) or no treatment at all. The groups are followed up to see how effective the experimental treatment was. Outcomes are measured at specific times and any difference in response between the groups is assessed statistically. This method is also used to reduce bias.
RCT	See 'Randomised controlled trial'.

Term	Definition
Receiver operated characteristic (ROC) curve	A graphical method of assessing the accuracy of a diagnostic test. Sensitivity is plotted against 1 minus specificity. A perfect test will have a positive, vertical linear slope starting at the origin. A good test will be somewhere close to this ideal.
Reference standard	The test that is considered to be the best available method to establish the presence or absence of the outcome – this may not be the one that is routinely used in practice.
Reporting bias	See ‘Publication bias’.
Resource implication	The likely impact in terms of finance, workforce or other NHS resources.
Retrospective study	A research study that focuses on the past and present. The study examines past exposure to suspected risk factors for the disease or condition. Unlike prospective studies, it does not cover events that occur after the study group is selected.
Review question	In guideline development, this term refers to the questions about treatment and care that are formulated to guide the development of evidence-based recommendations.
Risk ratio (RR)	<p>The ratio of the risk of disease or death among those exposed to certain conditions compared with the risk for those who are not exposed to the same conditions (for example, the risk of people who smoke getting lung cancer compared with the risk for people who do not smoke).</p> <p>If both groups face the same level of risk, the risk ratio is 1. If the first group had a risk ratio of 2, subjects in that group would be twice as likely to have the event happen. A risk ratio of less than 1 means the outcome is less likely in the first group. The risk ratio is sometimes referred to as relative risk.</p>
Secondary outcome	An outcome used to evaluate additional effects of the intervention deemed a priori as being less important than the primary outcomes.
Selection bias	<p>Selection bias occurs if:</p> <ul style="list-style-type: none"> a) The characteristics of the people selected for a study differ from the wider population from which they have been drawn, or b) There are differences between groups of participants in a study in terms of how likely they are to get better.
Sensitivity	<p>How well a test detects the thing it is testing for.</p> <p>If a diagnostic test for a disease has high sensitivity, it is likely to pick up all cases of the disease in people who have it (that is, give a ‘true positive’ result). But if a test is too sensitive it will sometimes also give a positive result in people who don’t have the disease (that is, give a ‘false positive’).</p> <p>For example, if a test were developed to detect if a woman is 6 months pregnant, a very sensitive test would detect everyone who was 6 months pregnant, but would probably also include those who are 5 and 7 months pregnant.</p> <p>If the same test were more specific (sometimes referred to as having higher specificity), it would detect only those who are 6 months pregnant, and someone who was 5 months pregnant would get a negative result (a ‘true negative’). But it would probably also miss some people who were 6 months pregnant (that is, give a ‘false negative’).</p> <p>Breast screening is a ‘real-life’ example. The number of women who are recalled for a second breast screening test is relatively high</p>

Term	Definition
	because the test is very sensitive. If it were made more specific, people who don't have the disease would be less likely to be called back for a second test but more women who have the disease would be missed.
Sensitivity analysis	<p>A means of representing uncertainty in the results of economic evaluations. Uncertainty may arise from missing data, imprecise estimates or methodological controversy. Sensitivity analysis also allows for exploring the generalisability of results to other settings. The analysis is repeated using different assumptions to examine the effect on the results.</p> <p>One-way simple sensitivity analysis (univariate analysis): each parameter is varied individually in order to isolate the consequences of each parameter on the results of the study.</p> <p>Multi-way simple sensitivity analysis (scenario analysis): 2 or more parameters are varied at the same time and the overall effect on the results is evaluated.</p> <p>Threshold sensitivity analysis: the critical value of parameters above or below which the conclusions of the study will change are identified.</p> <p>Probabilistic sensitivity analysis: probability distributions are assigned to the uncertain parameters and are incorporated into evaluation models based on decision analytical techniques (for example, Monte Carlo simulation).</p>
Significance (statistical)	A result is deemed statistically significant if the probability of the result occurring by chance is less than 1 in 20 ($p < 0.05$).
Specificity	<p>The proportion of true negatives that are correctly identified as such. For example in diagnostic testing the specificity is the proportion of non-cases correctly diagnosed as non-cases.</p> <p>See related term 'Sensitivity'.</p> <p>In terms of literature searching a highly specific search is generally narrow and aimed at picking up the key papers in a field and avoiding a wide range of papers.</p>
Stakeholder	<p>An organisation with an interest in a topic that NICE is developing a guideline or piece of public health guidance on. Organisations that register as stakeholders can comment on the draft scope and the draft guidance. Stakeholders may be:</p> <ul style="list-style-type: none"> • manufacturers of drugs or equipment • national patient and carer organisations • NHS organisations • organisations representing healthcare professionals.
State transition model	See Markov model
Stratification	When a different estimate effect is thought to underlie two or more groups based on the PICO characteristics. The groups are therefore kept separate from the outset and are not combined in a meta-analysis, for example; children and adults. Specified a priori in the protocol.
Sub-groups	Planned statistical investigations if heterogeneity is found in the meta-analysis. Specified a priori in the protocol.
Systematic review	A review in which evidence from scientific studies has been identified, appraised and synthesised in a methodical way according to predetermined criteria. It may include a meta-analysis.

Term	Definition
Time horizon	The time span over which costs and health outcomes are considered in a decision analysis or economic evaluation.
Transition probability	In a state transition model (Markov model), this is the probability of moving from one health state to another over a specific period of time.
Treatment allocation	Assigning a participant to a particular arm of a trial.
Univariate	Analysis which separately explores each variable in a data set.
Utility	In health economics, a 'utility' is the measure of the preference or value that an individual or society places upon a particular health state. It is generally a number between 0 (representing death) and 1 (perfect health). The most widely used measure of benefit in cost–utility analysis is the quality-adjusted life year, but other measures include disability-adjusted life years (DALYs) and healthy year equivalents (HYEs).

1
2

Acronyms and abbreviations

Acronym or abbreviation	Description
ARD	Absolute Risk Difference
AS	Active Surveillance
ATA	American Thyroid Association
BTA	British Thyroid Association
CEUS	Contrast Enhanced Ultrasound
CI	Confidence intervals
CND	Central Neck Dissection
CT	Computerised Tomography
DTC	Differentiated Thyroid Cancer
EBR	External Beam Radiation
EBRT	External Beam Radiation Treatment
ETE	Extra Thyroidal Extension
FNA	Fine Needle Aspiration (see FNAC)
FNAB	Fine Needle Aspiration Biopsy (see FNAC)
FNAC	Fine Needle Aspiration Cytology
FN	False Negative
FP	False Positive
PET	Positron Emission Tomography
GBq	Gigabecquerel
GC	Guideline Committee
GRADE	Grading of recommendations, assessment, development and evaluation.
HR	Hazard ratio
HT	Hemithyroidectomy
IQR	Interquartile Range
IPD	Individual Patient Data
LN	Lateral Node
L-T3	Levothyroxine
L-T4	Liothyronine
mCi	Millicuries
MD	Mean Difference
MIBI	Dipyridamole/technetium sestamibi scans (more commonly known as MIBI scans, an acronym for methoxyisobutyl isonitrile)
MRI	Magnetic Resonance imaging
NGC	National Guideline Centre
NICE	National Institute for Health and Care Excellence
NMA	Network Meta-analysis
OR	Odds ratio
PMC	Papillary microcarcinoma

Acronym or abbreviation	Description
PTC	Papillary Thyroid Cancer
PTMC	Papillary Thyroid Microcarcinoma
QALY	Quality adjusted life year
RAI	Radioactive Iodine Ablation
RCT	Randomised Controlled Trial
Rh TSH	Recombinant TSH (thyrotrophin alpha, thyrogen)
ROSA	Rapid On-Site Assessment
RR	Risk ratio (also known as relative risk)
RTE	Real Time Elastography
SD	Standard deviation
SR	Systematic Review
SWE	Shear Wave Elastography
T3	Thyroxine
T4	Triiodothyronine
THYCA-QoL	THYroid CANCER-Quality of Life scale
THW	Thyroid Hormone Withdrawal
TIRADS	Thyroid Imaging Reporting and Data System
TN	True Negative
TNM	Tumour (T), nodes N) and metastases (M)
TP	True Positive
TPO	Thyroid peroxidase antibody test
TSH	Thyroid Stimulating Hormone
TT	Total Thyroidectomy
US	Ultrasound

1

2

3

4

5

6

References

1. GRADE Working Group. The grading of recommendations assessment, development and evaluation (grade) working group website. 2011. Available from: <http://www.gradeworkinggroup.org/> Last accessed:
2. McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V, Lefebvre C. PRESS Peer Review of Electronic Search Strategies: 2015 Guideline Statement. *Journal of Clinical Epidemiology*. 2016; 75:40-46
3. National Institute for Health and Care Excellence. Developing NICE guidelines: the manual. London. National Institute for Health and Care Excellence, 2014. Available from: <http://www.nice.org.uk/article/PMG20/chapter/1%20Introduction%20and%20o%20view>
4. National Institute for Health and Care Excellence. Developing NICE guidelines: the manual [updated 2020]. London. National Institute for Health and Care Excellence, 2014. Available from: <http://www.nice.org.uk/article/PMG20/chapter/1%20Introduction%20and%20o%20view>
5. National Institute for Health and Care Excellence. Developing NICE guidelines: the manual [updated October 2018]. London. National Institute for Health and Care Excellence, 2014. Available from: <http://www.nice.org.uk/article/PMG20/chapter/1%20Introduction%20and%20o%20view>
6. National Institute for Health and Care Excellence. The NICE Charter. 2020. Available from: <https://www.nice.org.uk/about/who-we-are/our-charter> Last accessed: 24/03/2022.
7. National Institute for Health and Clinical Excellence. Social value judgements: principles for the development of NICE guidance. London. National Institute for Health and Clinical Excellence, 2008. Available from: <https://www.nice.org.uk/media/default/about/what-we-do/research-and-development/social-value-judgements-principles-for-the-development-of-nice-guidance.pdf>
8. Novielli N, Cooper NJ, Abrams KR, Sutton AJ. How is evidence on test performance synthesized for economic decision models of diagnostic tests? A systematic appraisal of Health Technology Assessments in the UK since 1997. *Value in Health*. 2010; 13(8):952-957
9. Organisation for Economic Co-operation and Development (OECD). Purchasing power parities (PPP). 2021. Available from: <http://www.oecd.org/std/ppp> Last accessed: 24/03/2022.
10. Reitsma JB, Glas AS, Rutjes AW, Scholten RJ, Bossuyt PM, Zwinderman AH. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. *Journal of Clinical Epidemiology*. 2005; 58(10):982-990

- 1 11. Review Manager (RevMan) [Computer program]. Version 5. Copenhagen.
2 The Nordic Cochrane Centre, The Cochrane Collaboration, 2015. Available
3 from: <http://tech.cochrane.org/Revman>
- 4 12. WinBUGS [Computer programme] version 1.4. Cambridge. MRC Biostatistics
5 Unit University of Cambridge, 2015. Available from: [http://www.mrc-
7 bsu.cam.ac.uk/software/bugs/the-bugs-project-winbugs/](http://www.mrc-
6 bsu.cam.ac.uk/software/bugs/the-bugs-project-winbugs/)